Device control method, insulin infusion device, program product and closed-loop infusion system

Abstract

The invention relates to an equipment control method, insulin infusion equipment, a program product and a closed-loop infusion system, the equipment is applied to the insulin infusion equipment, the insulin infusion equipment comprises a touch screen, at least one memory and at least one processor, the touch screen is used for receiving user input, the memory stores executable instructions, and the processor is used for processing the executable instructions. When the processor executes the executable instructions, the processor is used for realizing the following method: monitoring whether a blood glucose influence event occurs during the operation period of the closed-loop operation mode; the blood glucose influence event comprises an event that the blood glucose level of the user is out of the target blood glucose range of the control parameter due to equipment operation and / or user activity; triggering a safety protection program under the condition that the occurrence of the blood glucose influence event is determined; and carrying out safety management on the closed-loop operation mode of the insulin infusion equipment through a safety protection program.

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a device control method, an insulin infusion device, a program product, and a closed-loop infusion system. Background Art

[0002] Diabetes is a common metabolic endocrine disease caused by a chronic metabolic disorder resulting from an inadequate production of the hormone insulin by the pancreas, leading to hyperglycemia (excessive glucose in the plasma). Currently, there is no cure for diabetes, and external insulin infusion remains an effective means of controlling blood sugar.

[0003] In the prior art, insulin infusion devices use a closed-loop operating mode to simulate an artificial pancreas for infusion control. However, certain events that may occur during closed-loop operation, such as device malfunction and user hypoglycemia, can affect the safety of this closed-loop operation. Managing the safety of this closed-loop operation is a pressing issue. Summary of the Invention

[0004] Based on this, it is necessary to provide a device control method, insulin infusion device, program product and closed-loop infusion system that can improve the safety management of closed-loop operation mode in response to the above technical problems.

[0005] In a first aspect, the present application provides a device control method, which is applied to an insulin infusion device. The insulin infusion device includes a touch screen, at least one memory, and at least one processor. The touch screen is used to receive user input, and the memory stores executable instructions. When the processor executes the executable instructions, it is used to implement the following method:

[0006] In response to a first interactive operation of the user on the parameter graphic element displayed on the touch screen, obtaining a control parameter input by the user;

[0007] In response to a second interaction operation by the user on a device connection graphic element displayed on the touch screen, establishing a communication connection with the blood glucose monitoring device through the second interaction operation to receive a blood glucose measurement value sent by the blood glucose monitoring device;

[0008] In response to a third user interaction operation on a mode start graphic element displayed on the touch screen, the closed-loop operation mode is activated through the third interaction operation; wherein the activation of the closed-loop operation mode is prohibited if a communication connection with the blood glucose monitoring device is not established;

[0009] In the case of closed-loop operation mode, the insulin infusion device is controlled to operate in the corresponding infusion mode according to the blood glucose measurement value, historical infusion data and control parameters;

[0010] Monitor whether blood glucose impact events occur during the closed-loop operation mode; blood glucose impact events include events that cause the user's blood glucose level to deviate from the target blood glucose range of the control parameters due to device operation and / or user activities;

[0011] When a blood sugar impact event is determined to have occurred, the safety protection procedure is triggered;

[0012] Safety management of the closed-loop operation mode of insulin infusion equipment is achieved through safety protection procedures.

[0013] In a second aspect, the present application also provides an insulin infusion device, which includes a touch screen, at least one memory and at least one processor, the memory stores executable instructions, and the processor is used to execute the executable instructions to implement the above-mentioned device control method.

[0014] In a third aspect, the present application also provides a program product, which implements the above-mentioned device control method when executed by a processor.

[0015] In a fourth aspect, the present application also provides a closed-loop infusion system, which includes the above-mentioned insulin infusion device.

[0016] The device control method, insulin infusion device, program product, and closed-loop infusion system described above can, in response to a first user interaction with a parameter graphical element displayed on a touch screen, obtain a control parameter input by the user, and use the control parameter to initiate or maintain the closed-loop operating mode of the insulin infusion device. Furthermore, in response to a second user interaction with a device connection graphical element displayed on the touch screen, a communication connection is established with a blood glucose monitoring device through the second interaction to receive blood glucose measurement values ​​transmitted by the blood glucose monitoring device. Furthermore, in response to a third user interaction with a mode activation graphical element displayed on the touch screen, the closed-loop operating mode can be initiated through the third interaction. In this way, the insulin infusion device can be intuitively and efficiently controlled and the closed-loop operating mode initiated through the touch screen. Furthermore, because the activation of the closed-loop operating mode is prohibited if a communication connection with the blood glucose monitoring device is not established, the reliability of the activation of the closed-loop operating mode is improved. Furthermore, when running in a closed-loop operation mode, the insulin infusion device can be controlled to operate in a corresponding infusion mode according to blood glucose measurement values, historical infusion data and control parameters, and whether a blood glucose impact event occurs during the operation of the closed-loop operation mode can be monitored. When it is determined that a blood glucose impact event has occurred, a safety protection program is triggered, and the closed-loop operation mode of the insulin infusion device is safely managed through the safety protection program. In addition, blood glucose impact events include events in which the user's blood glucose level deviates from the target blood glucose range of the control parameters due to device operation and / or user activities. In this way, when a blood glucose impact event occurs, the blood glucose impact event can be responded to in a timely manner, and the closed-loop operation mode can be safely managed efficiently, thereby improving the safety of the closed-loop operation mode. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present application or related technologies, the following briefly introduces the drawings required for use in the embodiments of the present application or related technical descriptions. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying any creative work.

[0018] Figure 1 is a schematic structural diagram of an insulin infusion device according to an embodiment;

[0019] Figure 2 1 is a flow chart of a device control method in one embodiment;

[0020] Figure 3 FIG1 is a schematic diagram of a process for operating a temporary basal rate infusion mode in one embodiment;

[0021] Figure 4FIG1 is a schematic diagram of another flow chart for operating a temporary basal rate infusion mode in one embodiment;

[0022] Figure 5 FIG1 is a schematic diagram of a process for setting a large dose infusion dose in one embodiment;

[0023] Figure 6 FIG1 is a schematic diagram of a process for operating a large-dose infusion mode in one embodiment;

[0024] Figure 7 1 is a flow chart of yet another device control method according to an embodiment;

[0025] Figure 8 is a schematic diagram of a menu page in one embodiment;

[0026] Figure 9 is a schematic diagram of yet another menu page in one embodiment;

[0027] Figure 10 is a schematic diagram of yet another menu page in one embodiment;

[0028] Figure 11 A schematic diagram of a CGM setting interface according to an embodiment;

[0029] Figure 12 is a schematic diagram of a binding mode in one embodiment;

[0030] Figure 13 This is a control parameter setting interface in an embodiment. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solutions and advantages of this application more clear, the following further describes this application in detail with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain this application and are not intended to limit this application.

[0032] Figure 1 This is a schematic diagram of the structure of an insulin infusion device in one embodiment. The device control method provided in this embodiment can be applied to Figure 1 Insulin infusion equipment as shown. Figure 1 As shown, the insulin infusion device 100 includes a touch screen 101 , at least one memory 102 and at least one processor 103 .

[0033] The touch screen 101 is used to receive user input, that is, to perform human-computer interaction. The touch screen 101 can be implemented by a display element such as a liquid crystal display (LCD), a light emitting diode (LED) display, or an active-matrix organic light emitting diode (AMOLED).

[0034] The memory 102 stores executable instructions. The memory 102 may be a volatile memory or a non-volatile memory, or may include both volatile and non-volatile memory. The non-volatile memory may be a read-only memory (ROM), a programmable read-only memory (PROM), an erasable programmable read-only memory (EPROM), an electrically erasable programmable read-only memory (EEPROM), or a flash memory. The volatile memory may be a random access memory (RAM), which is used as an external cache.

[0035] When the processor 103 executes the executable instructions in the memory, the following device control method can be implemented. The processor 103 includes but is not limited to at least one of a central processing unit (CPU), a digital signal processor (DSP), a field programmable gate array (FPGA), or other programmable logic devices.

[0036] Figure 2 FIG. 1 is a flow chart of a device control method in an embodiment. In an exemplary embodiment, as shown in FIG. Figure 2 As shown, a device control method is provided, which is applied to Figure 1 The processor in the insulin infusion device in the embodiment is used as an example for explanation, that is, when the processor executes the executable instructions, it is used to implement the following steps S201 to S207.

[0037] S201 : In response to a first interactive operation of a user on a parameter graphic element displayed on a touch screen, obtaining a control parameter input by the user.

[0038] In this embodiment, the touch screen can display graphical elements, such as function icons. The graphical elements can be pre-set or user-defined. Optionally, each graphical element can be associated with a function and / or application (app) provided by the insulin infusion device.

[0039] The graphical element includes a parameter graphical element. Furthermore, the user can initiate a first interactive operation with respect to the parameter graphical element displayed on the touch screen. The first interactive operation may include, but is not limited to, touch input such as gesture touch, capacitive pen touch, or other non-touch input. The other interactive operations described below are similar and will not be further described.

[0040] For example, the user may click on a parameter graphic element displayed on the touch screen and input a control parameter through the touch screen to initiate the first interactive operation. Thereafter, the processor may obtain the control parameter input by the user in response to the first interactive operation.

[0041] The control parameters are used to initiate or maintain the closed-loop operating mode of the insulin infusion device. The control parameters can also be understood as the parameters required to operate the closed-loop operating mode. The control parameters include at least a target blood glucose range, which represents the desired range within which the user's blood glucose measurement falls. Optionally, the target blood glucose range may include upper and lower limits for ideal blood glucose measurement values, such as a target blood glucose range of 90 mg / dL to 120 mg / dL.

[0042] Further optionally, the control parameters may also include at least one parameter of the insulin action duration (DIA), target blood glucose (BG), carbohydrate ratio (ICR) and insulin sensitivity factor (ISF).

[0043] Alternatively, the control parameters provided in this embodiment include, for example, insulin sensitivity coefficient, daily insulin requirement, insulin limit, reference basal rate, reference fasting blood glucose, duration of active insulin action, pharmacodynamic time constant, target blood glucose range, weight parameters, etc.

[0044] The control parameters may also include control parameters utilized to automatically adjust the operating mode of the insulin infusion device in a personalized manner based on the current or real-time operating context (e.g., time of day, day of the week, location of the patient, activities or behaviors engaged in by the patient, etc.), such as control targets or references for a closed-loop operating mode. For example, based on an analysis of the relationship between the patient's historical blood glucose measurement data and corresponding blood glucose-affecting events during operation in the closed-loop operating mode, correlations between specific blood glucose-affecting events and abnormal physiological states or conditions of the patient, such as high glucose (or hyperglycemia) events (e.g., glucose levels above a threshold), low glucose (or hypoglycemia) events (e.g., glucose levels below a threshold), blood glucose abnormalities, etc. In this regard, events in which the user's blood glucose level deviates from the target blood glucose range of the control parameters due to device operation and / or user activity are improved by the device control method proposed in the present application.

[0045] Insulin infusion device control modes include closed-loop and open-loop modes. Open-loop mode refers to a control mode in which the insulin infusion device adjusts the infusion mode according to a preset or user-defined method. Closed-loop mode refers to a control mode in which the insulin infusion device, in conjunction with a blood glucose monitoring device, automatically adjusts the infusion mode based on blood glucose changes.

[0046] The infusion mode of an insulin infusion device controls its operation. These modes include bolus mode, basal rate mode, and stop mode. Stop mode pauses the insulin infusion. Bolus mode allows the device to deliver a large dose over a specified period of time to maintain insulin needs for meals, exercise, and other specific needs.

[0047] Bolus infusion modes can include conventional bolus infusion mode, square wave infusion mode, or dual wave infusion mode. Conventional bolus infusion mode refers to an infusion mode that completes the infusion in one go. For example, if 15 units (U) of insulin need to be infused immediately, the insulin infusion device can be controlled to execute conventional bolus infusion mode to complete the infusion of 15 U in one go. Square wave infusion mode refers to an infusion mode that completes the infusion within the infusion duration. In other words, square wave infusion mode refers to a mode in which a large dose is injected over a period of time. For example, if 15 U need to be infused within 2 hours, the insulin infusion device can be controlled to execute square wave infusion mode to complete the infusion of 15 U in 2 hours. Dual wave infusion mode includes conventional bolus infusion mode and square wave infusion mode. For example, if a user needs to infuse 7 U immediately and 5 U within 2 hours, the dual wave bolus infusion mode can be executed to control the insulin infusion device to complete the infusion of 7 U in one go and 5 U within 2 hours.

[0048] A basal rate infusion mode refers to a continuous, low-dose infusion mode over a period of time, used to maintain daily metabolism. Basal rate infusion modes can include standard basal rate infusion mode and temporary basal rate infusion mode. Standard basal rate infusion mode refers to a mode that infuses a standard basal rate at a preset interval. Temporary basal rate infusion mode refers to a mode that infuses a temporary basal rate at a preset interval.

[0049] S202 , in response to a second interaction operation of the user on the device connection graphic element displayed on the touch screen, establish a communication connection with the blood glucose monitoring device through the second interaction operation to receive a blood glucose measurement value sent by the blood glucose monitoring device.

[0050] In this embodiment, the graphic element also includes a device connection graphic element. Then, the user can initiate a second interactive operation with respect to the device connection graphic element displayed on the touch screen. The second interactive operation is used to establish a communication connection between the insulin infusion device and the blood glucose monitoring device. In this way, the processor can respond to the second interactive operation and establish a communication connection with the blood glucose monitoring device through the second interactive operation. The blood glucose monitoring device with which the communication connection is established can be a blood glucose monitoring device specified by the user, or a blood glucose monitoring device selected from a plurality of candidate blood glucose monitoring devices searched for, and this embodiment is not limited thereto.

[0051] The blood glucose monitoring device includes, but is not limited to, a continuous glucose monitor (CGM). The blood glucose monitoring device is used to obtain the user's blood glucose measurement value. Furthermore, when the processor establishes a communication connection with the blood glucose monitoring device, the processor can receive the blood glucose measurement value sent by the blood glucose monitoring device.

[0052] Further optionally, the processor may receive the blood glucose measurement value monitored by the blood glucose monitoring device in real time, or may periodically or aperiodically receive the blood glucose measurement value sent by the blood glucose monitoring device. For example, the processor may receive the blood glucose measurement value sent by the blood glucose monitoring device every second. For example, the processor may receive the user's blood glucose measurement value 1 at the first second, the blood glucose measurement value 2 at the second second, the blood glucose measurement value 3 at the third second, and so on.

[0053] It is understood that the insulin infusion device and the blood glucose monitoring device may be connected by wired communication or wireless communication. Wired communication connection includes, but is not limited to, a Universal Serial Bus (USB) connection, a serial communication connection, and an Ethernet connection. Wireless communication interfaces include, but are not limited to, Bluetooth connection, Wireless Fidelity (WIFI) connection, and ZigBee connection, which are not limited in this embodiment.

[0054] S203, in response to the user's third interactive operation on the mode start graphic element displayed on the touch screen, starting the closed-loop operation mode through the third interactive operation; wherein, if a communication connection is not established with the blood glucose monitoring device, starting the closed-loop operation mode is prohibited.

[0055] In this embodiment, the graphical element also includes a device mode activation element. Furthermore, the user can initiate a third interactive operation with respect to the mode activation graphical element displayed on the touch screen. The third interactive operation is used to activate the closed-loop operation mode. Thus, the processor can respond to the third interactive operation and activate the closed-loop operation mode through the third interactive operation.

[0056] Optionally, the processor may, when a communication connection is established with the blood glucose monitoring device, initiate the closed-loop operation mode in response to a user's third interactive operation with respect to a mode-initiating graphic element displayed on the touch screen. Further, the processor may, when the closed-loop operation mode is not initiated and a communication connection is established with the blood glucose monitoring device, initiate the closed-loop operation mode in response to a user's third interactive operation with respect to a mode-initiating graphic element displayed on the touch screen.

[0057] Furthermore, if a communication connection is not established with the blood glucose monitoring device, the processor will prohibit starting the closed-loop operation mode.

[0058] Optionally, the processor may not respond to the third interactive operation if a communication connection with the blood glucose monitoring device has not been established. That is, if a user initiates the third interactive operation on the mode activation graphical element displayed on the touch screen without establishing a communication connection with the blood glucose monitoring device, the processor will not respond to the third interactive operation and will not initiate the closed-loop operation mode, thereby prohibiting the initiation of the closed-loop operation mode.

[0059] Further optionally, the processor may also adjust the background color of the mode startup graphic element without establishing a communication connection with the blood glucose monitoring device. For example, the processor may adjust the background color of the startup graphic element to gray to remind the user that the closed-loop operation mode is currently prohibited.

[0060] S204: In the case of a closed-loop operation mode, the insulin infusion device is controlled to operate in a corresponding infusion mode according to the blood glucose measurement value, the historical infusion data and the control parameters.

[0061] In this embodiment, when operating in a closed-loop mode, the processor can automatically control the insulin infusion device to operate in a corresponding infusion mode based on the blood glucose measurement value, historical infusion data, and control parameters. The historical infusion data indicates the insulin infusion device's historical infusion status, and may include, for example, the insulin infusion status of the insulin infusion device within a historical time period prior to the current moment. The historical time period can be set based on actual needs. For example, the historical infusion data may indicate when and how much insulin was infused by the insulin infusion device within the two days prior to the current moment.

[0062] Optionally, the processor may control the insulin infusion device to operate in a corresponding infusion mode according to the control parameters, the blood glucose measurement value at the current moment, and the historical infusion data before the current moment.

[0063] Further optionally, a first correspondence may be established between the blood glucose measurement value, historical infusion data, control parameters, and infusion mode. The first correspondence may include, but is not limited to, a mathematical expression or a mathematical model. The processor may then determine a corresponding infusion mode based on the blood glucose measurement value, historical infusion data, control parameters, and the first correspondence.

[0064] Further optionally, the processor may input the blood glucose measurement value, historical infusion data, and control parameters into a first machine learning model, and the first machine learning model may output a corresponding infusion pattern to control the insulin infusion device to operate the corresponding infusion pattern. The first machine learning model may be trained based on blood glucose measurement value samples, historical infusion data samples, control parameter samples, and corresponding infusion patterns.

[0065] Exemplarily, the first machine learning model may include, but is not limited to, a convolutional neural network (CNN) model, a recurrent neural network (RNN) model, a fully convolutional neural network (FCN) model, a generative adversarial network (GAN) model, a back-propagation (BP) machine learning model, a radial basis function (RBF) model, a deep belief network (DBN) model, an Elman model, or at least one of a combination thereof. The following other machine learning models are similar and will not be described in detail.

[0066] S205, monitoring whether a blood glucose impact event occurs during the operation of the closed-loop operation mode; a blood glucose impact event includes an event in which the user's blood glucose level deviates from the target blood glucose range of the control parameters due to device operation and / or user activity.

[0067] In this embodiment, the processor can monitor blood glucose impact events during the closed-loop operation mode. That is, the processor monitors whether at least one blood glucose impact event occurs during the closed-loop operation mode.

[0068] Among them, blood glucose impact events include events in which the user's blood glucose level deviates from the target blood glucose range of control parameters due to device operation and / or user activity. Device operation refers to the operation of the insulin infusion device and / or the operation of the blood glucose monitoring device. Exemplarily, blood glucose impact events may include user hypoglycemia events, blood glucose loss events, abnormal blood glucose events, and strong magnetic environment events.

[0069] Optionally, the processor may determine whether a blood glucose impact event has occurred during the closed-loop operation mode by monitoring the operating status of the insulin infusion device and / or the operating status of the blood glucose monitoring device. The processor may also determine whether a blood glucose impact event has occurred during the closed-loop operation mode by monitoring blood glucose measurements. The processor may also monitor whether a blood glucose impact event has occurred during the closed-loop operation mode based on user input, although this embodiment is not limited thereto.

[0070] S206: When it is determined that a blood sugar impact event has occurred, a safety protection program is triggered.

[0071] In this embodiment, if the processor detects a blood sugar impact event during operation in the closed-loop operating mode, the processor triggers a safety protection program. The safety protection program is a program that can be run on the processor. After the safety protection program is triggered, the processor can execute the safety protection program.

[0072] Optionally, the safety protection program can be stored in a preset space. When a blood sugar impact event is determined to have occurred, the processor can call the safety protection program from the preset space to trigger the safety protection program. In some embodiments, the safety protection program can also be installed in the insulin infusion device.

[0073] S207, performing safety management on the closed-loop operation mode of the insulin infusion device through a safety protection program.

[0074] In this embodiment, the safety protection program is used to perform safety management on the closed-loop operation mode, that is, the safety protection program can be used to process blood sugar impact events so that the changed blood sugar level of the user is restored to the target blood sugar range. Therefore, when the safety protection program is triggered, the processor can perform safety management on the closed-loop operation mode of the insulin infusion device through the safety protection program. Optionally, the safety management of the closed-loop operation mode may include shutting down the closed-loop operation mode or maintaining the closed-loop operation mode. Maintaining the closed-loop operation mode includes maintaining or adjusting the infusion mode corresponding to the insulin infusion device.

[0075] In the above-mentioned device control method, in response to a first user interaction operation on a parameter graphic element displayed on a touch screen, a control parameter input by the user is obtained, and the control parameter is used to start or maintain the closed-loop operation mode of the insulin infusion device. Furthermore, in response to a second user interaction operation on a device connection graphic element displayed on the touch screen, a communication connection is established with a blood glucose monitoring device through the second interaction operation to receive blood glucose measurement values ​​sent by the blood glucose monitoring device. Furthermore, in response to a third user interaction operation on a mode start graphic element displayed on the touch screen, the closed-loop operation mode is started through the third interaction operation. In this way, the insulin infusion device can be controlled intuitively and efficiently through the touch screen, and the closed-loop operation mode can be started. Furthermore, because the start of the closed-loop operation mode is prohibited if a communication connection with the blood glucose monitoring device is not established, the reliability of starting the closed-loop operation mode is improved. Furthermore, when running in a closed-loop operation mode, the insulin infusion device can be controlled to operate in a corresponding infusion mode according to blood glucose measurement values, historical infusion data and control parameters, and whether a blood glucose impact event occurs during the operation of the closed-loop operation mode can be monitored. When it is determined that a blood glucose impact event has occurred, a safety protection program is triggered, and the closed-loop operation mode of the insulin infusion device is safely managed through the safety protection program. Since blood glucose impact events include events in which the user's blood glucose level deviates from the target blood glucose range of the control parameters due to device operation and / or user activities, in this way, when a blood glucose impact event occurs, the blood glucose impact event can be responded to in a timely manner, and the closed-loop operation mode can be safely managed efficiently, thereby improving the safety of the closed-loop operation mode.

[0076] Figure 3 FIG. 1 is a flow chart of a method for operating a temporary basal rate infusion mode in an embodiment. In an exemplary embodiment, as shown in FIG. Figure 3 As shown, the processor is further configured to implement the following steps S301 to S306:

[0077] S301: Receive motion information collected by a motion sensor or input by a user.

[0078] In this embodiment, the processor can determine motion information, wherein the motion information is used to characterize the user's motion conditions, including but not limited to the user's motion state, motion duration, motion distance, motion speed, motion amount, or motion trajectory.

[0079] Optionally, the processor may receive motion information collected by a motion sensor, such as an acceleration sensor.

[0080] Optionally, the processor may also receive motion information input by a user. For example, a user may input their own motion information through a touch screen.

[0081] Furthermore, the processor may receive motion information collected by a motion sensor or input by a user during the closed-loop operation mode.

[0082] S302: Determine whether a user motion event occurs according to the motion information.

[0083] In this embodiment, the blood sugar impact event includes a user exercise event, which refers to an event in which the user's blood sugar level drops outside the target blood sugar range due to the user's exercise. In other words, the user exercise event has an impact on the blood sugar level.

[0084] Furthermore, the processor receives the motion information and determines whether a user motion event has occurred based on the running information. For example, the processor may analyze the motion information and determine that a user motion event has occurred if the motion information meets a motion trigger condition. Motion trigger conditions may include, for example, motion duration exceeding a preset motion duration, motion volume exceeding a preset motion volume, or the motion state being running. This embodiment is not limited to these conditions.

[0085] S303: When it is determined that a user motion event occurs, trigger a safety protection program.

[0086] The principle is the same as that of S206. When it is determined that a user motion event has occurred, the processor can trigger the safety protection program.

[0087] S304: Obtain the blood glucose measurement value at the current moment when the user's exercise event occurs, and determine the blood glucose prediction value based on the exercise information, the blood glucose measurement value, and the historical blood glucose data.

[0088] In this embodiment, when the safety protection program is triggered, the processor can determine at least one blood glucose prediction value after a user motion event occurs through the safety protection program. In this embodiment, the blood glucose prediction value refers to the blood glucose value predicted based on the blood glucose measurement value after the user motion event has occurred. User motion events have an impact on future blood glucose. Therefore, according to the safety protection program's security management of the current user operation event, the blood glucose prediction value can be determined based on the current blood glucose measurement value, motion information, and historical blood glucose data at the moment when the user motion event occurs, thereby automatically adjusting the infusion dose according to blood glucose changes, ensuring the safe operation of the closed-loop infusion mode, and addressing the impact of user motion events on blood glucose changes.

[0089] In one embodiment, the processor can determine the blood glucose prediction value based on the motion information, the current blood glucose measurement value, the historical infusion data, and the control parameters. The current blood glucose measurement value can be the blood glucose measurement value sent by the blood glucose monitoring device when the blood glucose prediction value needs to be determined. Optionally, a second correspondence between the motion information, the blood glucose measurement value, the historical infusion data, the control parameters, and the blood glucose prediction value can be established. The second correspondence can include but is not limited to a mathematical expression or a mathematical model. Then, the processor can determine the blood glucose prediction value based on the motion information, the current blood glucose measurement value, the historical infusion data, the control parameters, and the above-mentioned second correspondence.

[0090] The processor may also input the exercise information, current blood glucose measurement value, historical infusion data, and control parameters into a second machine learning model, which may output a corresponding blood glucose prediction value. The second machine learning model may be trained based on exercise information samples, blood glucose measurement value samples, historical infusion data samples, control parameter samples, and corresponding blood glucose prediction values.

[0091] In one embodiment, the processor can also determine the blood glucose predicted value based on motion information, current blood glucose measurement value and historical blood glucose data. Wherein, the historical blood glucose data indicates the historical blood glucose situation of the insulin infusion device, for example, and can include the blood glucose situation of the insulin infusion device in the historical time period before the current moment, and the historical time period can be set according to actual needs. Exemplarily, the historical blood glucose data can include the blood glucose measurement value received within 2 days before the current moment.

[0092] For example, a third correspondence between exercise information, blood glucose measurement values, historical blood glucose data, and blood glucose prediction values ​​can be established. The third correspondence may include, but is not limited to, a mathematical expression or a mathematical model. Then, the processor determines the blood glucose prediction value based on the exercise information, the current blood glucose measurement value, the historical blood glucose data, and the third correspondence. The processor may also input the exercise information, the current blood glucose measurement value, and the historical blood glucose data into a third machine learning model, and the third machine learning model outputs the corresponding blood glucose prediction value. The third machine learning model can be trained based on the exercise information samples, the blood glucose measurement value samples, the historical blood glucose data samples, and the corresponding blood glucose prediction values.

[0093] In one embodiment, the processor can also determine the blood glucose prediction value based on the motion information and historical blood glucose data. For example, a fourth correspondence between the motion information, the historical blood glucose data and the blood glucose prediction value can be established. The fourth correspondence can include but is not limited to a mathematical expression or a mathematical model. Then, the processor determines the blood glucose prediction value based on the motion information, the historical blood glucose data and the above-mentioned fourth correspondence. The processor can also input the motion information and the historical blood glucose data into a fourth machine learning model, and the fourth machine learning model outputs the corresponding blood glucose prediction value. The fourth machine learning model can be trained based on the motion information sample, the historical blood glucose data sample and the corresponding blood glucose prediction value.

[0094] S305, through the safety protection program, determine the infusion dose of the temporary basal rate according to the blood glucose prediction value and control parameters.

[0095] After determining the predicted blood glucose value after the user's exercise event, the processor can determine the temporary basal rate infusion dose based on the predicted blood glucose value and the control parameters through the safety protection program. For example, a corresponding relationship between the predicted blood glucose value, the control parameters, and the temporary basal rate infusion dose can be established, so that the processor can determine the temporary basal rate infusion dose based on the predicted blood glucose value, the control parameters, and the corresponding relationship. The corresponding relationship can include, but is not limited to, a mathematical expression or a mathematical model.

[0096] S306: Control the insulin infusion device to operate in a temporary basal rate infusion mode according to the infusion dose of the temporary basal rate.

[0097] In this embodiment, after determining the infusion dose of the temporary basal rate, the processor can control the insulin infusion device to operate the temporary basal rate infusion mode according to the infusion dose of the temporary basal rate. That is, the processor controls the insulin infusion device to infuse the temporary basal rate according to the infusion dose of the temporary basal rate to operate the temporary basal rate infusion mode.

[0098] It is understood that during the operation of the temporary basal rate infusion mode, the temporary basal rate infusion dose may change dynamically. For example, during the first five minutes, the processor may control the insulin infusion device to operate in the temporary basal rate infusion mode based on infusion dose A. During the second five minutes, the processor may control the insulin infusion device to operate in the temporary basal rate infusion mode based on infusion dose B.

[0099] In the above embodiment, it is possible to receive motion information collected by a motion sensor or input by a user, and determine whether a user motion event has occurred based on the motion information, so as to trigger a safety protection program when it is determined that a user motion event has occurred. Since it is possible to determine the blood glucose prediction value after the user motion event has occurred, and determine the temporary basal rate infusion dose based on the blood glucose prediction value and the control parameters through the safety protection program, in this way, when a user motion event occurs, it is possible to control the insulin infusion device to operate the temporary basal rate infusion mode based on the infusion dose of the temporary basal rate, and timely adjust the infusion dose of the temporary basal rate, so that the closed-loop operation mode is suitable for user motion scenarios, which is beneficial for restoring the user's blood glucose level to the target blood glucose range and improving safety.

[0100] Figure 4 FIG. 1 is a flow chart of another embodiment of a temporary basal rate infusion mode. In an exemplary embodiment, as shown in FIG. Figure 4 As shown, the processor is further configured to implement the following S401 to S405:

[0101] S401, determining the current blood sugar prediction value based on historical blood sugar data.

[0102] Among them, the historical blood glucose data may include historical blood glucose data of any period in the past. Optionally, the blood glucose prediction value at the current moment can be determined based on the blood glucose measurement value at the previous moment of the current moment. For example, based on the blood glucose measurement value at 10:30, the blood glucose prediction value at 10:35 can be determined. It should be noted that the previous moment of the current moment can be the previous moment adjacent to the current moment, or it can be the previous moment with a preset time interval from the current moment, and this embodiment is not limited to this.

[0103] The processor may determine the predicted blood glucose value based on the current blood glucose measurement value, historical infusion data, and control parameters. Alternatively, the processor may determine the predicted blood glucose value based on the current blood glucose measurement value and historical blood glucose data. Alternatively, the processor may determine the predicted blood glucose value based on historical blood glucose data. The method for determining the predicted blood glucose value may refer to S304 and will not be further described herein.

[0104] S402: Determine whether a user meal event occurs based on a blood glucose difference value between a current blood glucose measurement value and a current blood glucose prediction value, and / or a meal monitoring sensor worn by the user.

[0105] In this embodiment, the blood sugar impact event includes a user meal event, which refers to an event in which the user's blood sugar level rises and deviates from the target blood sugar range due to the user's meal.

[0106] Optionally, the processor may determine whether a user meal event has occurred based on a blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value. The current blood glucose prediction value is determined based on historical blood glucose data. Continuing with the above example, assuming the current time is 10:35, the processor may determine whether a user meal event has occurred based on the blood glucose difference between the blood glucose prediction value at 10:35 and the blood glucose measurement value at 10:35.

[0107] Further optionally, the processor may determine that a user meal event has occurred when a blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value is greater than a preset difference.

[0108] In some embodiments, the processor may also determine whether a user has eaten a meal based on a meal monitoring sensor worn by the user. The meal monitoring sensor may include a bone conduction sensor and / or a lip movement monitoring sensor to determine whether a meal has occurred by monitoring maxillary bone movement and / or lip movement monitoring.

[0109] In some embodiments, the meal monitoring sensor can be worn at a preset location such as the user's temple. For example, the meal monitoring sensor can send a meal signal to the processor when the vibration generated by the user exceeds a preset vibration threshold, so that the processor can determine the occurrence of a user meal event based on the meal signal.

[0110] In some embodiments, the processor may also determine whether a user meal event has occurred based on the blood glucose difference value and a meal monitoring sensor worn by the user. For example, the processor may determine that a user meal event has occurred if the blood glucose difference value is greater than a preset difference and a meal signal is received from the meal monitoring sensor. This embodiment is not limited to this.

[0111] Furthermore, the processor may determine whether a user meal event occurs based on the blood glucose difference value and / or a meal monitoring sensor worn by the user during the closed-loop operation mode.

[0112] S403: When it is determined that a user dining event has occurred, a safety protection program is triggered.

[0113] The principle is the same as that of S206. When it is determined that a user motion event has occurred, the processor can trigger the safety protection program.

[0114] S404, through the safety protection program, determine the infusion dose of the temporary basal rate according to the blood glucose prediction value and control parameters.

[0115] In this embodiment, when the safety protection program is triggered, the processor can determine the infusion dose of the temporary basal rate based on the predicted blood glucose value and the control parameter. The process of determining the infusion dose of the temporary basal rate can be referred to S305 and will not be repeated here.

[0116] S405: Control the insulin infusion device to operate in a temporary basal rate infusion mode according to the infusion dose of the temporary basal rate.

[0117] The principle of S405 is the same as that of S306 and will not be repeated here.

[0118] In the above embodiment, since the occurrence of a user meal event is monitored based on the blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value, and / or the meal monitoring sensor worn by the user, the user's meal event can be flexibly and accurately monitored. Thus, if a user meal event is determined to have occurred, a safety protection program can be triggered. The safety protection program determines the temporary basal rate infusion dose based on the blood glucose prediction value and control parameters. Based on the temporary basal rate infusion dose, the insulin infusion device is controlled to operate in a temporary basal rate infusion mode. Therefore, the closed-loop operation mode is also applicable to scenarios where the user is eating, facilitating the restoration of the user's blood glucose level to within the target blood glucose range and improving safety.

[0119] In some exemplary embodiments, optionally, the processor is further configured to implement the steps of the following method 1, method 2, or method 3.

[0120] Method 1 includes the following steps:

[0121] S1. Obtaining a carbohydrate value input by a user via a touch screen. The carbohydrate value represents the total amount of food consumed by the user. For example, the carbohydrate value is 50 grams. Optionally, the user can initiate a fourth interaction operation with respect to a meal assistance graphical element displayed on the touch screen, so that the processor responds to the fourth interaction operation and obtains the carbohydrate value input by the user.

[0122] S2, triggering a safety protection program based on the carbohydrate value. That is, after the processor obtains the carbohydrate value input by the user, it can trigger a safety protection program based on the carbohydrate value.

[0123] S3, through the safety protection program, determining the first large dose according to the carbohydrate value, the blood glucose measurement value associated with the carbohydrate value input by the user at the current moment, and the control parameters.

[0124] The "first initial bolus dose" refers to the first bolus dose to be infused after the user enters a carbohydrate value. The blood glucose measurement value associated with the moment the user enters the carbohydrate value can be the same blood glucose measurement value as the current moment the carbohydrate value was entered, or a blood glucose measurement value whose difference from the current moment the carbohydrate value was entered is within a preset difference range. For example, assuming the user enters a carbohydrate value at 10:35, the processor, through a safety protection program, can determine the first initial bolus dose based on the carbohydrate value at 10:35, the blood glucose measurement value at 10:35, and the control parameters. Of course, the processor, through a safety protection program, can also determine the first initial bolus dose based on the carbohydrate value at 10:35, the blood glucose measurement value at 10:40, and the control parameters, and this embodiment is not limited thereto.

[0125] Optionally, a fifth correspondence between the carbohydrate value, the blood glucose measurement value, the control parameter, and the bolus dose can be determined, so that the processor can determine the first initial bolus dose based on the carbohydrate value, the blood glucose measurement value associated with the moment the user inputs the carbohydrate value, the control parameter, and the fifth correspondence. The processor can also input the carbohydrate value, the blood glucose measurement value associated with the moment the user inputs the carbohydrate value, and the control parameter into a fifth machine learning model to obtain the first initial bolus dose output by the fifth machine learning model. The fourth machine learning model can be trained based on carbohydrate value samples, blood glucose measurement value samples, control parameter samples, and corresponding bolus doses.

[0126] S4: Control the insulin infusion device to operate in a bolus infusion mode according to the first large dose. That is, the processor controls the insulin infusion device to infuse according to the first large dose to operate in a bolus infusion mode.

[0127] S5, determining a predicted blood glucose value based on the blood glucose measurement value at the next moment after the current moment.

[0128] In this embodiment, the next moment of the current moment may be the next moment adjacent to the current moment, or the next moment separated from the current moment by a preset time period, but this embodiment is not limited thereto.

[0129] Furthermore, the processor can determine a predicted blood glucose value based on the blood glucose measurement value at the next moment after the current moment. It is understood that the determined predicted blood glucose value can be a predicted blood glucose value at the next future moment. Continuing with the above example, the processor can determine a predicted blood glucose value at 10:45 based on the blood glucose measurement value at 10:40.

[0130] Among them, the blood glucose prediction value can be determined based on the current blood glucose measurement value, historical infusion data, historical carbohydrate value and control parameters, or the blood glucose prediction value can be determined based on the current blood glucose measurement value and historical blood glucose data, or the blood glucose prediction value can be determined based on historical blood glucose data.

[0131] For example, the processor can determine a predicted blood glucose value based on the current blood glucose measurement value, historical infusion data, historical carbohydrate values, and control parameters. The historical carbohydrate values ​​indicate the user's historical carbohydrate intake, and may include, for example, the carbohydrate intake of the user in a historical time period before the current moment. For example, the historical carbohydrate values ​​may indicate when and how much carbohydrate the user consumed in the two days before the current moment.

[0132] Further optionally, a sixth correspondence between blood glucose measurement values, historical infusion data, historical carbohydrate values, control parameters, and blood glucose prediction values ​​can be established. The sixth correspondence may include, but is not limited to, a mathematical expression or a mathematical model. Then, the processor can determine the blood glucose prediction value based on the current blood glucose measurement value, historical infusion data, historical carbohydrate values, control parameters, and the aforementioned sixth correspondence. The processor can also input the current blood glucose measurement value, historical infusion data, historical carbohydrate values, and control parameters into a sixth machine learning model, and the sixth machine learning model outputs the corresponding blood glucose prediction value. The sixth machine learning model can be trained based on blood glucose measurement value samples, historical infusion data samples, historical carbohydrate value samples, control parameter samples, and corresponding blood glucose prediction values.

[0133] Alternatively, the processor may determine the blood glucose predicted value based on the current blood glucose measurement value and historical blood glucose data, or the processor may determine the blood glucose predicted value based on historical blood glucose data. The method for determining the blood glucose predicted value may refer to S304 and will not be described in detail here.

[0134] S6, through the safety protection program, determines the first large supplementary dose based on the blood glucose predicted value and control parameters.

[0135] In this embodiment, because the carbohydrate value entered by the user may not be accurate, the processor also determines a first supplemental bolus dose based on the predicted blood glucose value and control parameters through a safety protection program. The first supplemental bolus dose includes the bolus dose that the user still needs to infuse after the first initial bolus dose.

[0136] Optionally, a correspondence between the predicted blood glucose value, the control parameter, and the bolus infusion dose can be established, so that the processor can determine the first supplemental bolus dose based on the predicted blood glucose value, the control parameter, and the correspondence. The correspondence can include, but is not limited to, a mathematical expression or a mathematical model.

[0137] S7: Control the insulin infusion device to operate in a bolus infusion mode according to the first supplemental bolus dose. That is, the processor can control the insulin infusion device to infuse again according to the first supplemental bolus dose to continue the bolus infusion mode. The processor can control the insulin infusion device to operate in a bolus infusion mode according to the first supplemental bolus dose after the insulin infusion device has completed the bolus infusion mode according to the first initial bolus dose.

[0138] Method 2 includes the following steps:

[0139] S1. Obtaining a pre-meal bolus dose input by the user via the touch screen. The pre-meal bolus dose includes a large infusion dose that the user needs to infuse before a meal. For example, a pre-meal bolus dose of 10 U indicates that the user desires to infuse 10 U of insulin to maintain a specific meal requirement.

[0140] S2, triggering the safety protection program by taking a large dose before a meal. That is, after the processor obtains the large dose before a meal input by the user, it can trigger the safety protection program by taking a large dose before a meal.

[0141] S3. Determine, through the safety protection program, a second initial bolus dose based on the pre-meal bolus dose and the control parameters. In this embodiment, when the safety protection program is triggered, the processor can determine, through the safety protection program, the second initial bolus dose based on the pre-meal bolus dose and the control parameters. The first initial bolus dose refers to the first bolus dose to be infused after the user inputs the pre-meal bolus dose. For example, the processor can correct the pre-meal bolus dose based on the control parameters to obtain the second initial bolus dose.

[0142] S4: Control the insulin infusion device to operate in a large-dose infusion mode according to the second large-dose. The principle of S4 in the second method is similar to that of S4 in the first method, and will not be repeated here.

[0143] S5: Determine the predicted blood glucose value based on the blood glucose measurement value at the next moment after the current moment. The principle of S5 in the second method is the same as that of S5 in the first method, and will not be repeated here.

[0144] S6: The safety protection program determines a second supplemental bolus dose based on the predicted blood glucose value and control parameters. In this embodiment, since the pre-meal bolus dose entered by the user may not be accurate, the processor determines the second supplemental bolus dose based on the predicted blood glucose value and control parameters. The second supplemental bolus dose includes the bolus dose that the user still needs to infuse after the second initial bolus dose. The principles of S6 in Method 2 are similar to those of S6 in Method 1 and will not be further described here.

[0145] S7: Control the insulin infusion device to operate in a large-dose infusion mode according to the second supplementary large dose. The principle of S7 in the second method is the same as that of S7 in the first method, and will not be repeated here.

[0146] Method 3 includes the following steps:

[0147] S1, obtaining the pre-meal bolus dose input by the user through the touch screen. The principle of S1 in method 3 is the same as that of S1 in method 2 above, and will not be repeated here.

[0148] S2, triggering the safety protection program by taking a large dose before a meal. The principle of S2 in method three is the same as that of S2 in method two above, so it will not be repeated here.

[0149] S3. The safety protection program controls the insulin infusion device to operate in a bolus infusion mode according to the pre-meal bolus dose. In this embodiment, the processor controls the insulin infusion device to operate in a bolus infusion mode according to the pre-meal bolus dose. In other words, the processor infuses the insulin according to the pre-meal bolus dose specified by the user.

[0150] S4, based on the blood glucose measurement value at the next moment after the current moment, determine the blood glucose prediction value. The principle of S4 in the third method is the same as that of S5 in the second and first methods, and will not be repeated here.

[0151] S5: A third supplemental bolus dose is determined based on the predicted blood glucose value and control parameters through the safety protection program. The third supplemental bolus dose includes the bolus dose that the user still needs to infuse after the pre-meal bolus dose. S5 in Method 3 is similar in principle to S6 in Methods 2 and 1 above and will not be further described here.

[0152] S6, according to the third supplementary large dose, controls the insulin infusion device to operate in a large dose infusion mode. The principle of S6 in the third method is the same as that of S7 in the second and first methods, and will not be repeated here.

[0153] In the above embodiments, regardless of method one, method two or method three, it is possible to operate the bolus infusion mode based on the first bolus, and then control the insulin infusion device to operate the bolus infusion mode based on the supplementary bolus. In this way, the first bolus can be supplemented by the supplementary bolus, thereby reducing the phenomenon of inaccurate first bolus due to inaccurate user input, and improving the reliability of the bolus infusion mode.

[0154] Figure 5 FIG. 1 is a flow chart of setting a large dose of infusion dosage in one embodiment. In an exemplary embodiment, as shown in FIG. Figure 5 As shown, the processor is further configured to implement the following S501 to S505:

[0155] S501 : Receive an initial infusion dose for executing a large-dose infusion mode.

[0156] In this embodiment, the initial infusion dose may be an infusion dose input by a user or an infusion dose customized by a processor.

[0157] In one exemplary embodiment, the processor can optionally, in response to a fourth user interaction with a meal assistance graphical element displayed on the touch screen, obtain the carbohydrate value inputted in the fourth interaction, and receive the current blood glucose measurement value corresponding to the moment the user inputted the carbohydrate value, so as to generate a recommended bolus dose based on the carbohydrate value and / or the current blood glucose measurement value via a safety protection program. Furthermore, in response to a fifth user interaction with a bolus graphical element displayed on the touch screen, the processor can set an initial infusion dose based on the recommended bolus dose according to the fifth interaction and with reference to the recommended bolus dose.

[0158] For example, the user can click on the meal auxiliary graphic element displayed on the touch screen and enter the carbohydrate value through the touch screen to initiate the fourth interactive operation. In this way, the processor can obtain the carbohydrate value entered by the user in response to the fourth interactive operation.

[0159] The recommended bolus dose represents the bolus dose that the user needs to infuse when taking in the carbohydrate value, which can also be understood as a food bolus. Optionally, the processor can determine the recommended bolus dose based on the carbohydrate value entered by the user and / or the correspondence between the current blood glucose measurement value and the bolus. For example, in this correspondence, a 10 gram (g) carbohydrate value corresponds to a 10U bolus dose, 20g carbohydrate corresponds to a 15U bolus dose, etc., and the actual carbohydrate value entered by the user is 10g, the processor can determine that the recommended bolus dose is 10U.

[0160] The fifth interactive operation is used to set a bolus infusion dose based on the recommended bolus dose. When a user needs to set a bolus infusion dose based on the recommended bolus dose, the user initiates the fifth interactive operation with respect to the bolus dose graphic element displayed on the touch screen. For example, if the recommended bolus dose is 15U, the user can set the bolus infusion dose to 15U or make fine adjustments based on 15U. This allows the processor to receive the initial infusion dose for executing the bolus infusion mode.

[0161] S502: Monitor whether the initial infusion dose reaches the first infusion limit and the second infusion limit through a safety protection program.

[0162] The first infusion limit is used to constrain the total amount of large doses that are cumulatively infused within a preset time period. The preset time period is, for example, 4 hours, which can be set according to actual needs.

[0163] For example, under the first infusion limit, the total cumulative bolus infusion dose within 4 hours is not allowed to exceed a first threshold. If, during the process of setting the bolus infusion dose, it is determined that the total cumulative bolus infusion dose within 4 hours has reached the first threshold, the processor determines that the first infusion limit has been reached. In other words, the processor can determine whether the first infusion limit has been reached based on the initial infusion dose and the first threshold.

[0164] Further optionally, if, during the process of setting the bolus infusion dose, the processor determines that the total bolus infusion dose accumulated over a four-hour period has reached a first threshold, the processor may prompt the user to issue a first prompt message. In some embodiments, the processor may also stop setting the bolus infusion dose, for example, by exiting the bolus infusion setting interface, but this embodiment is not limited thereto.

[0165] The second infusion limit is used to constrain the total amount of bolus infusions administered during the day. For example, under the second infusion limit, the total amount of bolus infusions administered during the day is not allowed to exceed a second threshold. If, during the process of setting the bolus infusion amount, the total amount of bolus infusions administered during the day exceeds the second threshold, the processor determines that the second infusion limit has been reached. In other words, the processor can determine whether the second infusion limit has been reached based on the initial infusion dose and the second threshold.

[0166] Further, optionally, if the total cumulative bolus infusion doses received that day has reached a second threshold, the processor may prompt the user to issue a second prompt message. In some embodiments, the processor may also stop setting the bolus infusion dose, for example, by exiting the bolus infusion setting interface, but this embodiment is not limited thereto.

[0167] S503, when the initial infusion dose does not reach the first infusion limit and the second infusion limit, control the insulin infusion device to run the large-dose infusion mode; wherein the first infusion limit is used to constrain the total amount of large-dose infusion doses cumulatively input within a preset time period, and the second infusion limit is used to constrain the total amount of large-dose infusion doses cumulatively input within the day.

[0168] Furthermore, if the initial infusion dose does not reach the first infusion limit and the second infusion limit, the processor can control the insulin infusion device to operate in a large-dose infusion mode. In other words, the processor can control the insulin infusion device to operate in a large-dose infusion mode based on the initial infusion dose.

[0169] In the above embodiment, the carbohydrate value entered by the user can be obtained in response to the fourth user interaction with the meal assistance graphical element displayed on the touch screen, and a safety protection program can be triggered in response to the carbohydrate value. The safety protection program then determines a recommended bolus based on the carbohydrate value. Therefore, an appropriate recommended bolus can be determined based on the user's actual carbohydrate intake. Furthermore, since the first infusion limit is used to constrain the total cumulative bolus infusion dose entered via the bolus graphical element within a preset time period, and the second infusion limit is used to constrain the total cumulative second bolus infusion dose entered via the bolus graphical element within a given day, the safety of the bolus infusion mode can be enhanced by monitoring whether the initial infusion dose reaches the first and second infusion limits.

[0170] In an exemplary embodiment, optionally, when the initial infusion dose reaches the first infusion limit or the second infusion limit, the processor is further configured to implement at least one of the following methods:

[0171] (1) Calculate the dose difference between the initial infusion dose and the first infusion limit or the second infusion limit, and control the infusion dose difference of the insulin infusion device.

[0172] In this embodiment, optionally, if the first infusion limit is reached first, the processor calculates the dose difference between the initial infusion dose and the first infusion limit; if the second infusion limit is reached first, the processor calculates the dose difference between the initial infusion dose and the second infusion limit.

[0173] For example, if the first infusion limit is reached first, and the first threshold is 5 U, and before the initial infusion dose is infused, the cumulative bolus dose infused during the preset period is 4.5 U, while the initial infusion dose is 1 U, the processor can determine that the dose difference is 1-(5-4.5)=0.5 U. The second infusion limit is similarly defined and will not be further described here.

[0174] In this way, some of the user's infusion needs can be met while improving infusion safety.

[0175] (2) receiving an initial infusion dose input by the user on the touch screen, and, if the initial infusion dose reaches both the first infusion limit and the second infusion limit, controlling the touch screen to display a setting prompt to remind the user to reset the initial infusion dose. For example, if the initial infusion dose reaches both the first infusion limit and the second infusion limit, the processor may display a prompt on the touch screen stating “The daily infusion limit and the infusion limit within 4 hours have been reached. Please reset the infusion dose” to remind the user to reset the initial infusion dose.

[0176] Figure 6 FIG. 1 is a flow chart of a large-dose infusion mode in one embodiment. In an exemplary embodiment, as shown in FIG. Figure 6 As shown, the processor is further configured to implement the following S601 to S603:

[0177] S601, determining a current blood glucose prediction value based on historical blood glucose data, and determining a meal estimation value based on a blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value.

[0178] In this embodiment, after controlling the insulin infusion device to operate in a temporary basal rate infusion mode based on the temporary basal rate infusion dose, the processor can determine a current predicted blood glucose value based on the historical blood glucose data. The process of determining the current predicted blood glucose value based on the historical blood glucose data can be referred to above in S401 and will not be further described here.

[0179] Furthermore, based on the blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value, the meal estimation value can be determined. It is understood that the meal estimation value is a prediction value at a future time.

[0180] Optionally, the processor may establish a correspondence between blood glucose difference values ​​and meal estimation values, and determine the meal estimation value based on the actual blood glucose difference value and the correspondence. Alternatively, the processor may input the blood glucose difference value between the current measured blood glucose value and the current predicted blood glucose value into a trained meal estimation model, with the meal estimation model outputting the meal estimation value. The meal estimation value may be determined based on blood glucose difference value samples and corresponding meal estimation value samples.

[0181] S602, through the safety protection program, determine the micro-large dose according to the blood glucose prediction value, the meal estimation value and the control parameters.

[0182] In this embodiment, the processor can determine a micro-bolus dose based on the correspondence between the blood glucose prediction value, the meal estimation value, the control parameter, and the bolus dose. The micro-bolus dose is the bolus dose required after the temporary basal rate is infused.

[0183] S603, controlling the insulin infusion device to operate in a large-dose infusion mode according to the micro-large dose.

[0184] In this embodiment, after determining the micro-bolus dose, the processor can control the insulin infusion device to run the bolus infusion mode according to the micro-bolus dose, that is, control the insulin infusion device to infuse according to the micro-bolus dose to run the bolus infusion mode.

[0185] In the above embodiment, since the blood glucose prediction value and meal estimation value can be determined based on the historical blood glucose data and the blood glucose measurement value at the next moment after the current moment by triggering the safety protection program, and the micro-bolus dose can be determined based on the blood glucose prediction value, meal estimation value and control parameters through the safety protection program, so as to control the insulin infusion device to operate in the bolus infusion mode according to the micro-bolus dose, therefore, during the operation of the closed-loop operation mode, the user's blood glucose value can be predicted according to the actual situation after the temporary basal rate is infused, so that the user's blood glucose level can be maintained through single or multiple micro-boluses, thereby improving safety.

[0186] In some exemplary embodiments, optionally, the device control method may further include at least one of the following:

[0187] (1) When a hypoglycemic event is detected during operation in a closed-loop operation mode, the insulin infusion device is controlled to suspend infusion through a safety protection program.

[0188] In this embodiment, the processor can monitor whether a user hypoglycemia event has occurred during the closed-loop operation mode. A user hypoglycemia event refers to an event in which the user's blood glucose level falls below a normal level. For example, the insulin infusion device may determine that a user hypoglycemia event has occurred if all blood glucose measurements within a preset time period are below a hypoglycemia threshold. Alternatively, the device may determine that a user hypoglycemia event has occurred if a preset proportion of blood glucose measurements within a preset time period are below the hypoglycemia threshold. This embodiment is not limited to these.

[0189] Furthermore, when it is determined that a hypoglycemic event occurs during the closed-loop operation mode, the processor can control the insulin infusion device to suspend infusion through a safety protection program.

[0190] The processor can control the insulin infusion device to pause infusion by using a pause infusion function. Further, optionally, the insulin infusion device can control a drive mechanism in the insulin infusion device to be in a prohibited motion state to pause the infusion function. The drive mechanism can be used to drive a push mechanism of a reservoir in the insulin infusion device forward, causing the push mechanism to push insulin out of the reservoir.

[0191] In one embodiment, if a hypoglycemic event is determined to have occurred during the closed-loop mode, the processor may switch the closed-loop mode to the open-loop mode. After switching from the closed-loop mode to the open-loop mode, the processor may operate the infusion mode control mode according to a preset or user-specified method. For example, during the open-loop mode, the processor may infuse according to a user-specified standard basal rate.

[0192] (2) When it is determined that a hypoglycemic event has occurred during the operation of the closed-loop operation mode, monitor whether the insulin infusion device is operating in the standard basal rate infusion mode, and when it is determined that the insulin infusion device is operating in the standard basal rate infusion mode, adjust the standard basal rate infusion mode to the temporary basal rate infusion mode through the safety protection program, and set the infusion dose of the temporary basal rate to a safe dose.

[0193] In this embodiment, if a user hypoglycemia event is determined to have occurred during the closed-loop operation mode, the processor further monitors whether the insulin infusion device is currently operating in a standard basal rate infusion mode. In other words, if the insulin infusion device is currently infusing a standard basal rate when a user hypoglycemia event occurs, the processor determines that the insulin infusion device is currently operating in a standard basal rate infusion mode.

[0194] If it is determined that the insulin infusion device is operating in a standard basal rate infusion mode, the processor adjusts the standard basal rate infusion mode to a temporary basal rate infusion mode and sets the infusion dose of the temporary basal rate to a safe dose. In other words, the processor can set the infusion dose of the temporary basal rate to a safe dose and operate the temporary basal rate infusion mode based on the safe dose. In other words, the processor controls the insulin infusion device to infuse the temporary basal rate according to the safe dose.

[0195] The safety dose can be set based on actual needs and can be a value specified by the user based on experience or a value preset in the processor. In one embodiment, the safety dose is 0. It is understood that when the safety dose is 0, although the insulin infusion device is in the temporary basal rate infusion mode, the insulin infusion device will not infuse.

[0196] (3) When it is determined that a hypoglycemic event has occurred during the operation of the closed-loop operation mode, the system monitors whether the insulin infusion device is operating in the temporary basal rate infusion mode, and when it is determined that the insulin infusion device is operating in the temporary basal rate infusion mode, the system sets the temporary basal rate infusion dose to a safe dose through the safety protection program.

[0197] In this embodiment, if a user hypoglycemia event is determined to have occurred during the closed-loop operation mode, the processor further monitors whether the insulin infusion device is currently operating in a temporary basal rate infusion mode. In other words, if the insulin infusion device is currently infusing a temporary basal rate when a user hypoglycemia event occurs, the processor determines that the insulin infusion device is currently operating in a temporary basal rate infusion mode.

[0198] If it is determined that the insulin infusion device is operating in a temporary basal rate infusion mode, the processor may continue to set the temporary basal rate infusion dose to a safe dose through the safety protection procedure. In other words, the processor may determine that the temporary basal rate infusion dose is a safe dose. Optionally, the safe dose may be 0.

[0199] Then, the processor can run the temporary basal rate infusion mode according to the safety dose. That is, the processor controls the insulin infusion device to infuse the temporary basal rate according to the safety dose to run the temporary basal rate infusion mode.

[0200] (4) When monitoring a hypoglycemic event of the user during the closed-loop operation mode, monitor whether the insulin infusion device is running the temporary basal rate infusion mode and the large-dose infusion mode at the same time. If it is determined that the insulin infusion device is running the temporary basal rate infusion mode and the large-dose infusion mode, stop the large-dose infusion mode through the safety protection program, and set the temporary basal rate infusion dose to a safe dose through the safety protection program.

[0201] In this embodiment, if a user hypoglycemia event is determined to have occurred during the closed-loop operation mode, the processor further monitors whether the insulin infusion device is operating simultaneously in the temporary basal rate infusion mode and the bolus infusion mode. In other words, if the insulin infusion device is infusing a temporary basal rate and a bolus dose when a user hypoglycemia event occurs, the processor determines that the insulin infusion device is operating in the temporary basal rate infusion mode and the bolus infusion mode.

[0202] If the insulin infusion device is determined to be operating in both a temporary basal rate infusion mode and a bolus infusion mode, the processor will proceed through a safety protection procedure to, on the one hand, stop the bolus infusion mode, and, on the other hand, set the temporary basal rate infusion dose to a safe dose, thereby allowing the temporary basal rate infusion mode to operate according to the safe dose. In other words, the processor may set the currently operating temporary basal rate infusion dose to the safe dose. Optionally, the safe dose may be 0.

[0203] (5) When a hypoglycemic event is detected during the closed-loop operation mode, monitor whether the insulin infusion device is running in the large-dose infusion mode. If it is determined that the insulin infusion device is running in the large-dose infusion mode, stop the large-dose infusion mode through the safety protection program, run the temporary basal rate infusion mode through the safety protection program, and set the temporary basal rate infusion dose to a safe dose.

[0204] In this embodiment, if a user hypoglycemia event is determined to have occurred during the closed-loop operation mode, the processor further monitors whether the insulin infusion device is operating in a bolus infusion mode. Specifically, if the insulin infusion device is infusing a bolus dose, such as an initial bolus, supplemental bolus, or mini-bolus, when a user hypoglycemia event occurs, the processor determines that the insulin infusion device is operating in a bolus infusion mode.

[0205] If it is determined that the insulin infusion device is operating in a bolus infusion mode, the processor will continue to use the safety protection procedure to stop the bolus infusion mode and, on the other hand, operate the temporary basal rate infusion mode through the safety protection procedure and set the temporary basal rate infusion dose to a safe dose. In other words, the processor can set the infusion dose of the temporary basal rate to the safe dose to operate the temporary basal rate infusion mode according to the safe dose. Optionally, the safe dose can be 0.

[0206] In the above embodiment, through the safety management of user hypoglycemia events, when a user hypoglycemia event occurs, the corresponding infusion mode of the insulin infusion device can be adjusted to a safer state in a timely manner, thereby improving safety.

[0207] In an exemplary embodiment, optionally, after switching the closed-loop operation mode to the open-loop operation mode, the processor is further configured to implement at least one of the following methods:

[0208] (1) After the user's hypoglycemia event is resolved, in response to the user's sixth interactive operation on the mode start graphic element displayed on the touch screen, the insulin infusion device is controlled to resume the closed-loop operation mode.

[0209] In this embodiment, if the processor has switched the closed-loop operation mode to the open-loop operation mode, the processor may also restore the closed-loop operation mode, that is, switch the open-loop operation mode back to the closed-loop operation mode.

[0210] The user can manually restore the closed-loop operating mode. When the insulin infusion device is in open-loop operating mode and the user's hypoglycemia event has been resolved, the user can initiate a sixth interactive operation using the mode activation graphical element displayed on the touch screen. For example, the user can initiate the sixth interactive operation by clicking the mode activation graphical element. In this way, the processor can control the insulin infusion device to restore the closed-loop operating mode in response to the sixth interactive operation.

[0211] Here, releasing the user's hypoglycemia event may include the user releasing the hypoglycemia event according to a meal plan, or the user manually releasing the hypoglycemia event after replenishing blood sugar.

[0212] (2) When the blood glucose measurement value is detected to be higher than the blood glucose recovery threshold and the insulin infusion device is in the state of suspended infusion, the insulin infusion device is controlled to automatically resume the closed-loop operation mode.

[0213] In this embodiment, the processor can also automatically restore the closed-loop operating mode. When the insulin infusion device is in open-loop operating mode, the processor will continue to receive blood glucose measurements from the blood glucose monitoring device. If the blood glucose measurement is higher than the blood glucose recovery threshold and the insulin infusion device is in the process of pausing infusion, the processor will control the insulin infusion device to automatically restore the closed-loop operating mode. The blood glucose recovery threshold can be set according to actual conditions.

[0214] In some embodiments, the processor may also control the insulin infusion device to resume the closed-loop operation mode when it detects that the blood glucose measurement value is higher than the blood glucose recovery threshold and the insulin infusion device is in suspended infusion, and responds to the sixth interactive operation.

[0215] In the above embodiments, after the user's hypoglycemia event is resolved, in response to the user's sixth interactive operation of starting the graphic element for the mode displayed on the touch screen, the insulin infusion device is controlled to resume the closed-loop operation mode, or, when the blood glucose measurement value is monitored to be higher than the blood glucose recovery threshold and the insulin infusion device is in a state of suspended infusion, the insulin infusion device is controlled to automatically resume the closed-loop operation mode. Therefore, the closed-loop operation mode can also be efficiently restored manually and / or automatically.

[0216] In an exemplary embodiment, optionally, the processor is further configured to implement at least one of the following:

[0217] (1) When an abnormal blood sugar event or blood sugar loss event is determined to have occurred during the operation of the closed-loop operation mode, the closed-loop operation mode is maintained through the safety protection program, and the insulin infusion device is monitored to see whether it is running in the temporary basal rate infusion mode. If it is determined that the insulin infusion device is running in the temporary basal rate infusion mode, the temporary basal rate infusion mode is switched to the standard basal rate infusion mode.

[0218] (2) If an abnormal blood sugar event or blood sugar loss event is determined to have occurred during the operation of the closed-loop operation mode, the closed-loop operation mode shall be maintained through the safety protection procedure, and the insulin infusion device shall be monitored to see whether it is operating in the large-dose infusion mode. If it is determined that the insulin infusion device is operating in the large-dose infusion mode, the large-dose infusion mode shall be maintained.

[0219] (3) If an abnormal blood sugar event or blood sugar loss event is determined to have occurred during the operation of the closed-loop operation mode, the closed-loop operation mode shall be maintained through the safety protection program, and the insulin infusion device shall be monitored to see whether it is operating in the standard basal rate infusion mode. If the insulin infusion device is monitored to be operating in the standard basal rate infusion mode, the standard basal rate infusion mode shall be maintained.

[0220] In this embodiment, the processor can monitor whether an abnormal blood glucose event or a blood glucose loss event occurs during the closed-loop operation mode.

[0221] An abnormal blood glucose event indicates that the blood glucose measurement value received by the insulin infusion device is abnormal. The processor determines that an abnormal blood glucose event has occurred when abnormal changes occur in the blood glucose measurement values ​​within a preset time period. The abnormal change may be that all blood glucose measurement values ​​are higher than a first blood glucose threshold or lower than a second blood glucose threshold, or that a second preset proportion of blood glucose measurement values ​​are higher than the first blood glucose threshold or lower than the second blood glucose threshold. The difference between adjacent blood glucose measurement values ​​may also be outside the normal range, or that the rate of change of the blood glucose measurement values ​​is greater than a preset rate of change. This embodiment is not limited to these.

[0222] A blood glucose loss event indicates that the insulin infusion device has not properly received blood glucose measurement values. The processor may determine that a blood glucose loss event has occurred when the device has not received multiple consecutive blood glucose measurement values, or when the percentage of blood glucose measurement value losses reaches a preset percentage within a period of time, or when no blood glucose measurement values ​​have been received within a period of time. This embodiment is not limited thereto.

[0223] Furthermore, if it is determined that a hypoglycemic event has occurred during the closed-loop operation mode, the processor can maintain the closed-loop operation mode through a safety protection procedure.

[0224] While maintaining the closed-loop operating mode, the processor continues to monitor whether the insulin infusion device is operating in at least one of a temporary basal rate infusion mode, a bolus infusion mode, or a standard basal rate infusion mode.

[0225] Furthermore, if it is determined that the insulin infusion device is operating in a temporary basal rate infusion mode, the processor will switch the temporary basal rate infusion mode to a standard basal rate infusion mode. If the insulin infusion device is infusing a temporary basal rate, that is, the insulin infusion device is operating in a temporary basal rate infusion mode, the processor will switch the temporary basal rate infusion mode to a standard basal rate infusion mode. It is understood that after switching the temporary basal rate infusion mode to the standard basal rate infusion mode, the processor controls the insulin infusion device to infuse according to the standard basal rate to operate in the standard basal rate infusion mode. The standard basal rate can be a user-specified infusion dose or a preset infusion dose.

[0226] When determining that the insulin infusion device is running the bolus infusion mode, the processor maintains the bolus infusion mode. That is, if the insulin infusion device is infusing a bolus dose, that is, if the insulin infusion device is running the bolus infusion mode, the processor maintains the bolus infusion mode.

[0227] When the insulin infusion device is monitored to be running in a standard basal rate infusion mode, the processor maintains the standard basal rate infusion mode. That is, if the insulin infusion device is running in a standard basal rate infusion mode, the processor maintains the standard basal rate infusion mode.

[0228] In the above embodiment, timely response can be made even when an abnormal blood sugar event or a blood sugar loss event occurs, thereby improving the safety of the closed-loop operation mode.

[0229] In an exemplary embodiment, optionally, the processor is further configured to implement the following method:

[0230] When a high-level alarm event is determined to have occurred during the operation of the closed-loop operation mode, the closed-loop operation mode is switched to the open-loop operation mode through the safety protection program, and the high-level alarm event is safely managed.

[0231] In this embodiment, during the closed-loop operation mode, the processor further determines whether a high-level alarm event occurs. It should be noted that the high-level alarm event can be an alarm event of the insulin infusion device or an alarm event of the blood glucose monitoring device.

[0232] Furthermore, when a high-level alarm event is determined to have occurred during the operation of the closed-loop operation mode, the processor can switch the closed-loop operation mode to the open-loop operation mode through the safety protection program and perform safety management of the high-level alarm event.

[0233] The process of switching the closed-loop operation mode to the open-loop operation mode may refer to the above embodiment and will not be described in detail here.

[0234] Safety management of high-level alarm events may include, but is not limited to, controlling the insulin infusion device to suspend infusion, maintaining the standard basal rate infusion mode, and switching the temporary basal rate infusion mode to the standard basal rate infusion mode.

[0235] In the above embodiment, when a high-level alarm event is determined to have occurred during the operation of the closed-loop operation mode, the closed-loop operation mode can be switched to the open-loop operation mode through the safety protection program and the high-level alarm event can be safely managed, thereby reducing the safety risk.

[0236] In an exemplary embodiment, optionally, the high-level alarm event includes a first alarm event; and the processor is further configured to implement the following method:

[0237] According to the safety protection procedure for the safety management of the first alarm event, the insulin infusion device is controlled to suspend infusion.

[0238] In this embodiment, the first alarm event includes at least one of an excessively strong ambient magnetic field, depletion of medicine, detachment of a pipeline, depletion of power, and a pipeline blockage.

[0239] An excessively strong ambient magnetic field indicates that the insulin infusion device or blood glucose monitor is in a strong magnetic environment. The processor can obtain the magnetic field strength of the environment in which the insulin infusion device or blood glucose monitor is located and, if the magnetic field strength exceeds a safety threshold, determine that a high-level alarm event, indicating excessive ambient magnetic field strength, has occurred.

[0240] The depletion of medication indicates that the insulin infusion device is about to run out of medication. The processor may compare the current medication amount in the insulin infusion device with a medication depletion threshold, and determine that a high-level medication depletion alarm event has occurred if the current medication amount is less than the medication depletion threshold.

[0241] A line detachment event indicates that the line of the insulin infusion device's infusion set has detached from the user. The processor may determine that a high-level line detachment alarm event has occurred when the insulin infusion device is operating in an infusion mode and a change in a pressure value of a pressure sensor in the insulin infusion device is less than a preset change threshold.

[0242] Battery exhaustion indicates that the battery of the insulin infusion device is about to run out of power. The processor may compare the battery voltage of the insulin infusion device with a voltage exhaustion threshold value, and determine that a high-level battery exhaustion alarm event has occurred when the battery voltage is less than the voltage exhaustion threshold value.

[0243] A line blockage indicates that a line of an infusion set of an insulin infusion device is blocked. The processor may determine that a high-level alarm event of a line blockage has occurred when the insulin infusion device is operating in an infusion mode and a pressure value of a pressure sensor in the insulin infusion device is greater than a blockage threshold.

[0244] Furthermore, the processor can trigger a safety protection program in response to the first alarm event, and control the insulin infusion device to suspend infusion according to the safety protection program. In other words, once the first alarm event occurs, the processor can control the insulin infusion device to suspend infusion according to the safety protection program. The principles for controlling the insulin infusion device to suspend infusion can be found in the above-mentioned embodiment and will not be further elaborated here.

[0245] In the above embodiment, since the insulin infusion device can be controlled to suspend infusion in response to the first alarm event, it is possible to prevent infusion abnormalities caused by problems such as magnetic field, drug dosage, pipeline, and power.

[0246] In an exemplary embodiment, optionally, the high-level alarm event includes a second alarm event, and the processor is further configured to implement at least one of the following methods:

[0247] (1) According to the safety management of the second alarm event by the safety protection program, the temporary basal rate infusion mode currently running on the insulin infusion device is controlled to switch to the standard basal rate infusion mode.

[0248] (2) According to the safety protection procedure, the second alarm event is managed safely, and the insulin infusion device is controlled to maintain the standard basal rate infusion mode.

[0249] In this embodiment, the second alarm event may include that the service life of the blood glucose monitoring device is insufficient. The processor may determine whether the service life of the blood glucose monitoring device is insufficient based on the validity period of the received blood glucose measurement value.

[0250] Furthermore, during the open-loop operation mode, the processor may optionally control the insulin infusion device to switch from the temporary basal rate infusion mode to the standard basal rate infusion mode based on the safety management of the second alarm event by the safety protection program. That is, if the second alarm event of insufficient service life of the blood glucose monitoring device occurs while the insulin infusion device is currently operating in the temporary basal rate infusion mode, the processor will switch the temporary basal rate infusion mode to the standard basal rate infusion mode.

[0251] Optionally, the processor may also control the insulin infusion device to maintain the standard basal rate infusion mode based on the safety management of the second alarm event by the safety protection program. That is, if the second alarm event of insufficient service life of the blood glucose monitoring device occurs and the insulin infusion device is currently in the standard temporary basal rate infusion mode, the processor may continue to maintain the standard basal rate infusion mode.

[0252] Since the standard basal rate infusion can be maintained or restored in response to the second alarm event, the inaccuracy of the closed-loop control mode caused by the insufficient life of the blood glucose monitoring device can be avoided, thereby improving safety.

[0253] Figure 7 FIG. 1 is a flow chart of another device control method in an embodiment. In an exemplary embodiment, as shown in FIG. Figure 7 As shown, a device control method is also provided, which is applied to Figure 1 The processor in the insulin infusion device is used as an example for description, including the following S701 to S703.

[0254] S701, displaying a device connection graphic element on the touch screen; the device connection graphic element is used to guide the insulin infusion device to establish a communication connection with the blood glucose monitoring device.

[0255] For example, the touch screen of the insulin infusion device may include at least one of the main interface, menu page and negative one screen. Optionally, multiple user interfaces may be switched between. The user interface may also be understood as a human-computer interaction interface.

[0256] The graphic element includes a device connection graphic element, so that the insulin infusion device can display the device connection graphic element on the touch screen. Furthermore, the device connection graphic element is used to guide the insulin infusion device to establish a communication connection with the blood glucose monitoring device.

[0257] Figure 8 Schematic diagram of a menu page in one embodiment, such as Figure 8 As shown, the touch screen can display a menu page 800, and the graphic elements on the menu page 800 may include a device connection graphic element 802. Figure 8 For example, when the user needs to connect the insulin infusion device to the blood glucose monitoring device, the user can click the device connection graphic element 802 in the menu page 800 to initiate an interactive operation on the device connection graphic element 802. Then, the insulin infusion device can respond to the interactive operation and establish a communication connection with the blood glucose monitoring device.

[0258] S702: Receive blood sugar measurement values ​​monitored by a blood sugar monitoring device.

[0259] In this embodiment, the blood glucose monitoring device is used to obtain the blood glucose measurement value of the subject to be measured. When the insulin infusion device establishes a communication connection with the blood glucose monitoring device, the insulin infusion device can receive the blood glucose measurement value monitored by the blood glucose monitoring device through the communication interface.

[0260] S703 , in response to an interactive operation of a mode-starting graphic element displayed on the touch screen, controlling the insulin infusion device to enter a closed-loop operation mode.

[0261] In this embodiment, the graphical element also includes a mode activation graphical element. When the user desires to use the automatic infusion function, they can initiate an interactive operation with respect to the mode activation graphical element displayed on the touch screen. In this way, the insulin infusion device can respond to the interactive operation and control itself to enter the closed-loop operation mode.

[0262] Please continue to refer to Figure 3 For example, the graphic elements on the menu page 300 may include a mode start graphic element 301. When the user needs to automatically infuse a temporary basal rate, he or she may click on the mode start graphic element 301 to initiate an interactive operation on the mode start graphic element 301. Then, the insulin infusion device may enter a closed-loop operation mode in response to the interactive operation.

[0263] S704: If an abnormal event occurs during the operation of the closed-loop operation mode, the closed-loop operation mode is managed according to the infusion safety rules associated with the abnormal event.

[0264] In this embodiment, the insulin infusion device can monitor whether an abnormal event occurs during the operation in the closed-loop operation mode, wherein the abnormal event is also the above-mentioned blood sugar impact event.

[0265] Infusion safety rules are safety rules governing the closed-loop operating mode. These rules can be user-associated with abnormal events or pre-stored in the insulin infusion device, and are not limited to these rules in this embodiment. These rules can include, but are not limited to, at least one of stopping the temporary basal rate, maintaining the closed-loop operating mode, and disabling the closed-loop operating mode.

[0266] In the above-mentioned device control method, a device connection graphical element can be displayed on the touch screen. The device connection graphical element is used to guide the insulin infusion device to establish a communication connection with the blood glucose monitoring device. Furthermore, the device can receive blood glucose measurements from the blood glucose monitoring device and, in response to interactive operations initiated by the graphical element corresponding to the mode displayed on the touch screen, control the insulin infusion device to enter a closed-loop operation mode. Therefore, the user does not need to manually control the insulin infusion device. Furthermore, if an abnormal event occurs during the closed-loop operation mode, the closed-loop operation mode can be managed according to the infusion safety rules associated with the abnormal event. On the one hand, the user does not need to use physical buttons to control the insulin infusion device. Instead, the touch screen can intuitively and efficiently control the insulin infusion device to establish a communication connection with the blood glucose monitoring device and control the insulin infusion device to deliver a temporary basal infusion. This simplifies the operation steps of the insulin infusion device, makes the operation more simple, reduces the learning cost, and improves the control efficiency. On the other hand, because the closed-loop operation mode can be managed according to the infusion safety rules associated with the abnormal event, the safety of the insulin infusion device is improved.

[0267] In an exemplary embodiment, optionally, the “managing the closed-loop operation mode according to the infusion safety rules associated with the abnormal event” in S704 may include at least one of the following:

[0268] (1) In the event that the abnormal event includes a user hypoglycemic event, the infusion of the temporary basal rate is stopped according to the infusion safety rule associated with the user hypoglycemic event.

[0269] In this embodiment, since a user hypoglycemia event indicates that the subject's blood glucose level is below normal, continuing the infusion in this situation poses a risk. Therefore, the infusion safety rule associated with the user hypoglycemia event includes stopping the infusion of the temporary basal rate. Furthermore, if the abnormal event includes a user hypoglycemia event, that is, if a user hypoglycemia event occurs during operation in the closed-loop operating mode, the insulin infusion device will stop infusing the temporary basal rate.

[0270] In one embodiment, if the abnormal event includes a user hypoglycemia event, the insulin infusion device not only needs to stop infusing the temporary basal rate, but also needs to stop other infusions. That is, in the event of a user hypoglycemia event, the insulin infusion device can stop all infusions.

[0271] Optionally, the insulin infusion device can stop infusing the temporary basal rate by turning off the closed-loop operation mode. For example, the insulin infusion device can stop infusing the temporary basal rate by using a stop infusion function.

[0272] Alternatively, the insulin infusion device can control a drive mechanism within the device to a disabled state to stop the infusion function. The drive mechanism can be used to drive a push mechanism within the insulin infusion device's reservoir forward, causing the push mechanism to push insulin out of the reservoir. It is understood that in this case, the insulin infusion device will cease closed-loop operation and enter a stopped-infusion mode.

[0273] Optionally, the insulin infusion device may also stop infusing the temporary basal rate by setting the infusion dose of the temporary basal rate to 0. It is understandable that in this case, the insulin infusion device does not stop the closed-loop operation mode, but remains in the closed-loop operation mode.

[0274] In one embodiment, after the insulin infusion device stops infusing the temporary basal rate, if the blood glucose measurement value is within the normoglycemic range for a period of time, the temporary basal rate can be resumed. Optionally, after the insulin infusion device stops infusing the temporary basal rate, the temporary basal rate can be resumed in response to a user-triggered resume operation. The resume operation can be an interactive operation on a stop infusion graphic element on the touch screen, or an interactive operation on a mode activation graphic element.

[0275] (2) In the event of an abnormal event including a blood glucose loss event, the infusion closed-loop operation mode is maintained according to the infusion safety rules associated with the blood glucose loss event.

[0276] In this embodiment, the infusion safety rule associated with the blood glucose loss event includes maintaining the closed-loop operating mode. Furthermore, if the abnormal event includes a blood glucose loss event, that is, if the blood glucose loss event occurs during the closed-loop operating mode, the insulin infusion device will maintain the closed-loop operating mode.

[0277] Optionally, the insulin infusion device can maintain the closed-loop infusion mode based on a preset safety infusion dose, or can maintain the closed-loop infusion mode based on the last infusion dose during the closed-loop infusion mode. For example, if the insulin infusion device infuses a temporary basal rate based on infusion dose A during the first five minutes, and if a blood glucose loss event occurs between the first five minutes and the second five minutes, the insulin infusion device will continue to infuse the temporary basal rate based on infusion dose A during the second five minutes.

[0278] (3) In the event that the abnormal event includes an abnormal blood sugar event, the infusion of the temporary basal rate is stopped according to the infusion safety rules associated with the abnormal blood sugar event, and the insulin infusion device is controlled to enter the standard basal rate infusion mode.

[0279] In this embodiment, since an abnormal blood glucose event indicates an abnormal blood glucose measurement value received by the insulin infusion device, there are safety issues if a temporary basal rate is used based on the abnormal blood glucose measurement value. Therefore, the safety infusion rules for abnormal blood glucose events include stopping the infusion of the temporary basal rate and controlling the insulin infusion device to enter the standard basal rate infusion mode. Thus, if the abnormal event includes an abnormal blood glucose event, that is, if an abnormal blood glucose event occurs during operation in the closed-loop operation mode, the insulin infusion device will stop the infusion of the temporary basal rate and control the insulin infusion device to enter the standard basal rate infusion mode.

[0280] Optionally, the insulin infusion device can stop infusing the temporary basal rate by setting the infusion dose of the temporary basal rate to 0. The insulin infusion device can also stop infusing the temporary basal rate by turning off the closed-loop operation mode.

[0281] Standard basal rate infusion mode refers to a mode in which a standard basal rate is infused at a preset interval. For example, during standard basal rate infusion mode, the insulin infusion device may infuse a standard basal rate every 5 minutes. The standard basal rate can be user-defined, for example, the user can set the standard basal rate dosage for each infusion.

[0282] (4) In the event of an abnormal event including a strong magnetic environment event, the closed-loop operation mode is shut down according to the infusion safety rules associated with the strong magnetic environment event.

[0283] In this embodiment, the insulin infusion device can obtain the magnetic field strength of the environment in which the insulin infusion device is located, and determine that a strong magnetic environment event has occurred when the magnetic field strength is greater than a strength safety threshold.

[0284] Because using insulin infusion devices in strong magnetic environments poses a safety risk, the infusion safety rule associated with strong magnetic environment events includes disabling closed-loop operation mode. Furthermore, if the abnormal event includes a strong magnetic environment event—that is, if a strong magnetic environment event occurs during closed-loop operation—the insulin infusion device will disable closed-loop operation mode.

[0285] Alternatively, the insulin infusion device can stop delivering the temporary basal rate by using a stop infusion function. For example, the insulin infusion device can control a drive mechanism within the insulin infusion device to a disabled state to stop the infusion function. Alternatively, the insulin infusion device can disable closed-loop operation by shutting down the device, for example.

[0286] In some embodiments, if the abnormal event includes a strong magnetic environment event, the insulin infusion device not only needs to stop infusing the temporary basal rate, but also needs to stop other infusions. That is, in the event of a strong magnetic environment event, the insulin infusion device can stop all infusions.

[0287] In the above embodiment, since it is possible to stop the infusion of the temporary basal rate according to the infusion safety rules associated with the user hypoglycemia event when the abnormal event includes a user hypoglycemia event, maintain the infusion closed-loop operation mode according to the infusion safety rules associated with the blood glucose loss event when the abnormal event includes a blood glucose loss event, stop the infusion of the temporary basal rate according to the infusion safety rules associated with the blood glucose loss event when the abnormal event includes an abnormal blood glucose event, and control the insulin infusion device to enter the standard basal rate infusion mode when the abnormal event includes a strong magnetic environment event, close the closed-loop operation mode according to the infusion safety rules associated with the strong magnetic environment event, therefore, the closed-loop operation mode can be accurately and efficiently managed according to the infusion safety rules associated with the abnormal event to improve the safety of the insulin infusion device.

[0288] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0289] When the blood glucose measurement value within the first preset time period is higher than the first blood glucose threshold or lower than the second blood glucose threshold, the user's fingertip blood glucose measurement value is obtained, and it is determined whether a blood glucose impact event occurs based on the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device.

[0290] In this embodiment, the insulin infusion device is capable of monitoring blood glucose measurements. If the blood glucose measurements within a first preset time period are higher than a first blood glucose threshold or lower than a second blood glucose threshold, it indicates that there is a risk of abnormality in the blood glucose measurements. The blood glucose measurements within the first preset time period being higher than the first blood glucose threshold or lower than the second blood glucose threshold may mean that all blood glucose measurements within the first preset time period are higher than the first blood glucose threshold or lower than the second blood glucose threshold. The first and second blood glucose thresholds may be preset thresholds or thresholds input by the user via a touch screen.

[0291] Furthermore, if the blood glucose measurement value within the first preset time period is higher than a first blood glucose threshold or lower than a second blood glucose threshold, the insulin infusion device will obtain the user's fingertip blood glucose measurement value. The fingertip blood glucose measurement value represents the blood glucose measurement value of the subject's fingertip blood. The fingertip blood glucose measurement value can be a measurement value input by the user using a touch screen, or a measurement value sent by the insulin infusion device to another device.

[0292] The insulin infusion device then determines whether a blood glucose impact event has occurred based on the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device. Optionally, the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device may be measured at the same time, and the difference between the measurement time of the fingertip blood glucose measurement value and the measurement time of the blood glucose measurement value may be less than a preset time difference.

[0293] Further optionally, the insulin infusion device can compare the fingertip blood glucose measurement value with the blood glucose measurement value to determine whether a blood glucose-affecting event has occurred. For example, if the difference between the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device is within a preset difference range, it can be determined that a blood glucose-affecting event has not occurred; if the difference between the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device is not within the preset difference range, it can be determined that a blood glucose-affecting event has not occurred.

[0294] In the above embodiment, since the user's fingertip blood glucose measurement value can be obtained when the blood glucose measurement value within the first preset time period is higher than the first blood glucose threshold or lower than the second blood glucose threshold, it is possible to accurately determine whether a blood glucose impact event has occurred based on the fingertip blood glucose measurement value and the blood glucose measurement value monitored by the blood glucose monitoring device.

[0295] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0296] When the blood glucose measurement value monitored by the blood glucose monitoring device is not received within the second preset time period, the touch screen is controlled to display a blood glucose loss reminder, and / or the insulin infusion device is controlled to issue an alarm reminder.

[0297] In this embodiment, the insulin device can monitor the blood glucose value measured by the blood glucose monitoring device. Furthermore, if the insulin infusion device detects that it has not received the blood glucose value measured by the blood glucose monitoring device within a second preset time period, it can control the touch screen of the insulin infusion device to display a blood glucose loss reminder, or control the insulin infusion device to issue an alarm, or both control the touch screen to display the blood glucose loss reminder and control the insulin infusion device to issue an alarm.

[0298] The blood glucose level drop reminder may include, but is not limited to, textual reminders, graphic reminders, color-coded reminders, and voice reminders. The alarm corresponding to the blood glucose level drop may include, but is not limited to, a vibration alarm, a buzzer alarm, or a vibration and buzzer alarm. This embodiment does not limit the form and content of the blood glucose level drop reminder or alarm.

[0299] In the above embodiment, when the blood glucose measurement value monitored by the blood glucose monitoring device is not received within the second preset time period, the touch screen is controlled to display a blood glucose loss reminder, and / or the insulin infusion device is controlled to issue an alarm reminder, thereby being able to promptly remind the user of blood glucose loss.

[0300] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0301] In the event that the abnormal event includes a strong magnetic environment event, the touch screen is controlled to display a reminder that the environmental magnetic field is too strong, and / or the insulin infusion device is controlled to issue an alarm reminder.

[0302] In this embodiment, when the abnormal event includes a strong magnetic environment event, that is, when a strong magnetic environment event is detected, the insulin infusion device can control the touch screen of the insulin infusion device to display a reminder that the environmental magnetic field is too strong, or control the insulin infusion device to issue an alarm reminder, or both control the touch screen to display a reminder that the environmental magnetic field is too strong and control the insulin infusion device to issue an alarm reminder.

[0303] Similarly, reminders for excessively strong ambient magnetic fields may include, but are not limited to, textual reminders, graphic reminders, color-coded reminders, and voice reminders. Alarm reminders corresponding to strong magnetic environment events may include, but are not limited to, vibration alarms, buzzer alarms, or vibration and buzzer alarms. This embodiment does not limit the form and content of strong magnetic environment events and alarm reminders.

[0304] In the above embodiment, since when the abnormal event includes a strong magnetic environment event, the touch screen is controlled to display a reminder that the ambient magnetic field is too strong, and / or the insulin infusion device is controlled to issue an alarm reminder, the user can be promptly reminded that the insulin infusion device has entered a strong magnetic environment.

[0305] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0306] During the operation of the closed-loop operation mode, in response to the interactive operation of the meal assistance graphic element displayed on the touch screen, the insulin infusion device is controlled to enter the meal assistance mode; in response to the interactive operation of the large-dose infusion graphic element displayed on the touch screen, the insulin infusion device is controlled to execute the large-dose infusion mode; when the insulin infusion device enters the meal assistance mode and the large-dose infusion mode ends, the insulin infusion device is controlled to enter the micro-large-dose infusion mode.

[0307] In this embodiment, the graphic element further includes a meal assisting graphic element. In some blood sugar rising scenes, such as meal scenes, the user can enter the meal assisting mode through the meal assisting graphic element.

[0308] Optionally, during the closed-loop operation mode, the user can initiate an interactive operation with respect to a meal assistance graphical element displayed on the touch screen. In this way, the insulin infusion device can respond to the interactive operation and control itself to enter meal assistance mode. It is understood that entering meal assistance mode also activates the meal assistance function, and in meal assistance mode, the insulin infusion device can provide a bolus supplement.

[0309] In one embodiment, when the insulin infusion device enters the meal assistance mode, the insulin infusion device may be controlled to exit the meal assistance mode in response to an interactive operation on a meal assistance graphic element displayed on the touch screen.

[0310] For example, Figure 9 This is a schematic diagram of another menu page in an embodiment, please refer to Figure 8 and Figure 9 After the user clicks the mode start graphic element 801, the touch screen can display Figure 9 Interface 900 shown includes a meal assist graphical element 902. When a user clicks on meal assist graphical element 902, the insulin infusion device enters meal assist mode. After entering meal assist mode, the user can exit meal assist mode by clicking on meal assist graphical element 902 again.

[0311] In one embodiment, the closed-loop operation mode switch 901 is used to control the insulin infusion device to enter or exit the closed-loop operation mode. For example, when the insulin infusion device has not entered the closed-loop operation mode, the user can click the mode start graphic element 801, and the touch screen can display Figure 9 The user then clicks the closed-loop operation mode switch 901 in the interface 900 to control the insulin infusion device to enter the closed-loop operation mode. When the insulin infusion device enters the closed-loop operation mode, the user clicks the closed-loop operation mode switch 901 in the interface 900 again to control the insulin infusion device to exit the closed-loop operation mode.

[0312] When a large dose infusion is required, the user can initiate an interactive operation on the large dose infusion graphic element displayed on the touch screen, so that the insulin infusion device responds to the interactive operation and controls the insulin infusion device to execute the large dose infusion mode.

[0313] Figure 10 Schematic diagram of another menu page in one embodiment, such as Figure 10 As shown, the menu page 300 includes a bolus infusion graphic element 1002 , and the user clicks the bolus infusion graphic element 1002 to initiate an interactive operation, thereby controlling the insulin infusion device to perform a bolus infusion mode.

[0314] In this embodiment, after the infusion dose corresponding to the bolus infusion mode is completed, the bolus infusion mode ends. If the user has enabled the meal assist function in advance, that is, when the insulin infusion device enters the meal assist mode and the bolus infusion mode ends, the insulin infusion device can be controlled to enter the micro-bolus infusion mode. The micro-bolus infusion mode is a supplement to the bolus infusion mode and is used to control the insulin infusion device to infuse micro-boluses.

[0315] Optionally, when the insulin infusion device enters the meal assistance mode and the large-dose infusion mode ends, it is determined whether to start the micro-large-dose infusion mode, and when it is determined that the micro-large-dose infusion mode is started, the insulin infusion device is controlled to execute the micro-large-dose infusion mode.

[0316] Further optionally, the insulin infusion device can determine whether to activate the micro-bolus infusion mode based on the blood glucose measurement value and the control parameter, and, if the micro-bolus infusion mode is to be activated, the micro-bolus infusion dose can be infused according to the micro-bolus infusion dose to implement the micro-bolus infusion mode.

[0317] In the above embodiment, since during the operation of the closed-loop operation mode, the insulin infusion device can be controlled to enter the meal assistance mode in response to the interactive operation of the meal assistance graphic element displayed on the touch screen; the insulin infusion device can be controlled to execute the large-dose infusion mode in response to the interactive operation of the large-dose infusion graphic element displayed on the touch screen, and when the insulin infusion device enters the meal assistance mode and the large-dose infusion mode ends, the insulin infusion device is controlled to enter the micro-large-dose infusion mode. Therefore, it can be applied to some scenarios where blood sugar rises rapidly to supplement the large-dose infusion.

[0318] In one embodiment, please refer to Figure 10 The graphic elements further include a stop infusion graphic element 1001, which is used to stop the infusion function. For example, a user can click the stop infusion graphic element 1001 to enter the stop infusion mode, thereby controlling the drive mechanism in the insulin infusion device to a prohibited motion state, thereby stopping the infusion function.

[0319] In an exemplary embodiment, a device control method is further provided, which is described by taking the method applied to the processor in the figure as an example, and includes the following steps:

[0320] In response to interactive operations on the device connection graphic element displayed on the touch screen, a communication connection is established with the blood glucose monitoring device; the blood glucose measurement value monitored by the blood glucose monitoring device is received; the blood glucose measurement value is calibrated according to the calibration algorithm to determine the actual blood glucose value; in response to interactive operations on the mode start graphic element displayed on the touch screen, the insulin infusion device is controlled to enter the closed-loop operation mode; during the operation of the closed-loop operation mode, the insulin infusion device is controlled to operate the corresponding infusion mode according to the actual blood glucose value.

[0321] In this embodiment, the process of establishing a communication connection with the blood glucose monitoring device and receiving the blood glucose measurement value monitored by the blood glucose monitoring device can refer to the above embodiment.

[0322] However, due to the influence of environmental factors, the blood glucose measurement value sent by the blood glucose monitoring device may not be accurate. Therefore, in this embodiment, the processor calibrates the blood glucose measurement value according to the calibration algorithm to determine the actual blood glucose value.

[0323] The actual blood glucose value may represent the actual blood glucose of the subject to be tested. For example, the actual blood glucose value may include the actual blood glucose 1 of the subject to be tested at the first second, the actual blood glucose 2 at the second second, the actual blood glucose 3 at the third second, and so on.

[0324] The calibration algorithm may be an algorithm preset in the insulin infusion device, which may include but is not limited to a machine learning algorithm, a deviation compensation algorithm, and a dynamic calibration algorithm, but this embodiment is not limited thereto.

[0325] Entering the closed-loop operation mode is described in the above embodiment and will not be further described herein. Optionally, during the closed-loop operation mode, the processor may control the insulin infusion device to operate in a corresponding infusion mode based on the actual blood glucose value and a preset closed-loop control algorithm. Further, the processor may determine a predicted blood glucose value based on the actual blood glucose value, and control the insulin infusion device to operate in the corresponding infusion mode based on the predicted blood glucose value and the control parameters.

[0326] The preset closed-loop control algorithm may include, but is not limited to, a proportional-integral-derivative (PID) algorithm, a model predictive control (MPC) algorithm, a fuzzy logic (FL) algorithm, and the like.

[0327] In some embodiments, the preset closed-loop control algorithm can be implemented by means of a machine learning model, which may include but is not limited to a convolutional neural network (CNN) model, a recurrent neural network (RNN) model, a fully convolutional neural network (FCN) model, a generative adversarial network (GAN) model, a back-propagation (BP) machine learning model, a radial basis function (RBF) model, a deep belief network (DBN) model, an Elman model, or at least one of a combination thereof.

[0328] In one embodiment, if an abnormal event occurs during the closed-loop operation mode, the processor may further perform safety management on the closed-loop operation mode according to the infusion safety rules associated with the abnormal event. The process of performing safety management on the closed-loop operation mode can be referred to the above embodiment and will not be further described here.

[0329] In an exemplary embodiment, the graphic element optionally includes a finger blood calibration graphic element. The finger blood calibration graphic element can be used to update the calibration algorithm. The device control method further includes the following steps:

[0330] In response to an interactive operation on the finger blood calibration graphic element displayed on the touch screen, a fingertip blood glucose measurement value of the subject to be measured is obtained, and a calibration algorithm is updated according to the fingertip blood glucose measurement value and a blood glucose measurement value corresponding to the fingertip blood glucose measurement value.

[0331] For example, please refer to Figure 10 The user can click on the finger blood calibration graphic element 1003 to initiate an interactive operation on the finger blood calibration graphic element 1003, so that the processor responds to the interactive operation and obtains the fingertip blood glucose measurement value of the subject to be tested. The processor can communicate with the finger blood collection device to obtain the fingertip blood glucose measurement value of the subject to be tested through the finger blood collection device, or receive the fingertip blood glucose measurement value input by the user through the interactive interface.

[0332] The fingertip blood glucose measurement value corresponds to a blood glucose measurement value. The measurement time of the blood glucose measurement value may be the same as the measurement time of the fingertip blood glucose measurement value, and the difference between the measurement time of the blood glucose measurement value and the measurement time of the fingertip blood glucose measurement value may be less than a preset time difference. Furthermore, the processor may update the calibration algorithm based on the fingertip blood glucose measurement value and the blood glucose measurement value corresponding to the fingertip blood glucose measurement value.

[0333] Optionally, the processor may update the calibration algorithm based on the difference between the fingertip blood glucose measurement value and the blood glucose measurement value corresponding to the fingertip blood glucose measurement value. Updating the calibration algorithm may include, but is not limited to, updating parameters in the calibration algorithm.

[0334] In one embodiment, the processor can store the history of finger blood calibration, which is the process of updating the calibration algorithm. Figure 10 The finger blood calibration history graphic element 1004 is used to display the history of finger blood calibration. For example, after the user clicks the finger blood calibration history graphic element 1004, the touch screen can display the time when the user obtained the fingertip blood glucose measurement value, and updated the calibration algorithm based on the fingertip blood glucose measurement value and the blood glucose measurement value corresponding to the fingertip blood glucose measurement value.

[0335] In the above embodiment, since the graphic element includes a finger blood calibration graphic element and is capable of obtaining the fingertip blood glucose measurement value of the subject to be measured in response to interactive operations on the finger blood calibration graphic element displayed on the touch screen, and updating the calibration algorithm based on the fingertip blood glucose measurement value and the blood glucose measurement value corresponding to the fingertip blood glucose measurement value, the user can periodically update the calibration algorithm by himself to improve the accuracy of the actual blood glucose value.

[0336] In an exemplary embodiment, optionally, the above-mentioned “obtaining the fingertip blood glucose measurement value of the subject in response to an interactive operation on the finger blood calibration graphic element displayed on the touch screen” can be implemented as follows:

[0337] In response to an interactive operation on the finger blood calibration graphic element displayed on the touch screen, a finger blood input interface is displayed on the touch screen, and in response to a confirmation input based on the finger blood input interface and if the insulin infusion device meets preset conditions, the fingertip blood glucose measurement value input by the user is obtained.

[0338] In this embodiment, please continue to refer to Figure 10 After the user clicks on the fingertip blood calibration graphic element 1003, the processor may respond to the interactive operation on the fingertip blood calibration graphic element 1003 displayed on the touch screen and display a fingertip blood input interface (not shown) on the touch screen. The fingertip blood input interface may include an input control and a confirmation control. The input control may be, for example, an input box, and the confirmation control may be, for example, an "Confirm" button. The user may enter the collected fingertip blood glucose measurement value in the input space and, after completing the input, click the confirmation control to initiate a confirmation input based on the fingertip blood glucose input interface.

[0339] Then, the processor can obtain the fingertip blood glucose measurement value input by the user in response to the confirmation input based on the finger blood input interface and when the insulin infusion device meets the preset conditions.

[0340] The processor can determine whether the insulin infusion device meets the preset conditions. This step of determining whether the preset conditions are met can occur before or after responding to the confirmation input based on the finger blood input interface, and this embodiment is not limiting. For example, the processor can respond to the confirmation input based on the finger blood input interface and then determine whether the insulin infusion device meets the preset conditions. If it is confirmed that the insulin infusion device meets the preset conditions, the processor can obtain the fingertip blood glucose measurement value input by the user.

[0341] In one embodiment, optionally, the preset condition includes at least one of the following:

[0342] (1) The blood glucose measurement value within the third preset time period is within the preset blood glucose range. The third preset time period and the preset blood glucose range can be set as required. In one embodiment, the touch screen includes a home page, and the home page can include a trend of the blood glucose measurement value. The trend of the blood glucose measurement value can be represented by an arrow. When the trend arrow of the blood glucose measurement value is a flat arrow, slanted upward or slanted downward, it indicates that the blood glucose fluctuation is small, that is, the blood glucose measurement value within the third preset time period is within the preset blood glucose range.

[0343] (2) The blood glucose measurement value has not expired. The blood glucose measurement value sent by the blood glucose monitoring device has an expiration date. If the blood glucose measurement value exceeds the expiration date, it means that the blood glucose measurement value has expired, that is, the blood glucose measurement value received by the processor is incorrect. On the contrary, if the blood glucose measurement value has not exceeded the expiration date, it means that the blood glucose measurement value has not expired. At this time, the blood glucose measurement value received by the processor is relatively accurate, which is conducive to accurately updating the calibration algorithm. Optionally, the processor can determine whether the blood glucose measurement value has exceeded the expiration date based on the effective time of the blood glucose measurement value.

[0344] (3) The communication between the insulin infusion device and the blood glucose monitoring device is normal. Optionally, the processor can determine whether the communication between the insulin infusion device and the blood glucose monitoring device is normal through a heartbeat packet or other means.

[0345] In the above embodiment, since the finger blood input interface can be displayed on the touch screen in response to the interactive operation on the finger blood calibration graphic element displayed on the touch screen, and the fingertip blood glucose measurement value input by the user is obtained in response to the confirmation input based on the finger blood input interface and the insulin infusion device meets the preset conditions, the reliability of the fingertip blood glucose measurement value is improved.

[0346] In an exemplary embodiment, optionally, before responding to an interactive operation on the finger blood calibration graphic element displayed on the touch screen, the device control method further includes the following steps:

[0347] If the insulin infusion device does not meet the preset conditions, the finger blood calibration graphic element is controlled to be in a non-input state.

[0348] In this embodiment, controlling the finger blood calibration graphic element to be in a non-input state can be to set the background color of the finger blood calibration graphic element to a preset color, which can be but not limited to gray. Figure 10 Before the user clicks the finger blood calibration graphic element 1003, if the insulin infusion device does not meet the preset conditions, such as any one of the above three conditions, the processor will control the finger blood calibration graphic element 1003 to a non-input state.

[0349] In the above embodiment, if the insulin infusion device does not meet the preset conditions, the finger blood calibration graphic element is controlled to be in a non-input state. Therefore, when the preset conditions are not met, the calibration algorithm can be updated to avoid inaccurate fingertip blood glucose measurement values, which is beneficial to improving the accuracy of the actual blood glucose value.

[0350] Figure 11 This is a schematic diagram of a CGM setting interface in one embodiment. In an exemplary embodiment, the graphic elements may optionally further include a CGM binding graphic element and a CGM switch graphic element. The process of connecting the blood glucose monitoring device may be implemented as follows:

[0351] In response to an interactive operation on the CGM binding graphic element, the blood glucose monitoring device is bound; in response to a confirmation connection input after binding the blood glucose monitoring device, or in response to an interactive operation on the CGM switch graphic element, the blood glucose monitoring device is connected.

[0352] Please refer to Figure 8 , after the user clicks the device connection graphic element 802, the touch screen can display Figure 11 The CGM settings interface 1100 shown includes a CGM switch graphical element 1101 and a CGM binding graphical element 1102. After a user clicks on the CGM binding graphical element 1102, the processor can bind the blood glucose monitoring device in response to the interaction with the CGM binding graphical element. For example, the processor can store the device identifier of the blood glucose monitoring device to bind the blood glucose monitoring device.

[0353] Furthermore, after binding the blood glucose monitoring device, the touch screen can display a connection prompt, such as "Binding successful, do you want to connect the blood glucose monitoring device?" If the user clicks "Confirm connection", the confirmation connection input after binding the blood glucose monitoring device is initiated, and then the processor will connect the blood glucose monitoring device.

[0354] In some embodiments, after the touch screen displays "Binding successful, connect to blood glucose monitoring device?", the user can also exit the connection and not connect immediately. In this case, the CGM switch graphic element 1101 is in the off state. When it is necessary to connect the insulin infusion device and the blood glucose monitoring device, the user can click the CGM switch graphic element 1101, and the insulin infusion device will respond to the interactive operation on the CGM switch graphic element 1101 and then establish a connection with the blood glucose monitoring device.

[0355] In one embodiment, after the insulin infusion device and the blood glucose monitoring device are successfully connected, the touch screen can display a connection success prompt. In one embodiment, if the insulin infusion device and the blood glucose monitoring device fail to connect, the touch screen can display a connection failure prompt and prompt the user to try again.

[0356] In the above embodiment, since the blood glucose monitoring device can be bound in response to the interactive operation on the CGM binding graphic element, and the blood glucose monitoring device can be connected in response to the confirmation connection input after the binding of the blood glucose monitoring device, or the blood glucose monitoring device can be connected in response to the interactive operation on the CGM switch graphic element, the blood glucose monitoring device can be efficiently connected through the touch screen.

[0357] In an exemplary embodiment, optionally, the above-mentioned “binding the blood glucose monitoring device in response to an interactive operation on the CGM binding graphic element” can be implemented by the following steps:

[0358] In response to an interactive operation on a CGM binding graphic element, a target binding mode is selected from a plurality of binding modes displayed on the touch screen; a blood glucose monitoring device is determined according to the target binding mode; and a device identifier of the blood glucose monitoring device is stored to bind the blood glucose monitoring device.

[0359] In this embodiment, Figure 12 FIG. 1 is a schematic diagram of a binding mode in an embodiment, as shown in FIG. Figure 12 As shown, after the user clicks the CGM binding graphic element 1102, the touch screen will display multiple binding modes, for example, automatic binding 1201 and manual binding 1202 are displayed in the binding interface 1200. Then, the user can select the target binding mode from the multiple binding modes displayed on the touch screen.

[0360] The processor can then determine the blood glucose monitoring device based on the target binding mode. For example, if the user selects manual binding 1202, the user is required to specify the blood glucose monitoring device. If the user selects automatic binding 1201, the insulin infusion device can automatically determine the blood glucose monitoring device based on the communication signal quality. This embodiment does not impose any restrictions.

[0361] Furthermore, after the blood glucose monitoring device is determined, the device identification of the blood glucose monitoring device is also determined, and then the processor stores the device identification of the blood glucose monitoring device to bind the blood glucose monitoring device.

[0362] The device identification includes the serial number (SN) of the insulin infusion device and may also include a calibration code of the sensor, which is not limited in this embodiment.

[0363] In one embodiment, after binding the blood glucose monitoring device, the processor may display a successful binding prompt on the touch screen.

[0364] In the above embodiment, in response to the interactive operation on the CGM binding graphic element, the target binding mode is selected from the multiple binding modes displayed on the touch screen, and the blood glucose monitoring device is determined according to the target binding mode, and then the device identification of the blood glucose monitoring device is stored to bind the blood glucose monitoring device. Therefore, the blood glucose monitoring device can be accurately bound.

[0365] In an exemplary embodiment, optionally, the above-mentioned “determining the blood glucose monitoring device according to the target binding mode” can be implemented as follows:

[0366] If the target binding mode is the first binding mode, candidate blood glucose monitoring devices within the preset search range are searched, and in response to the user's selection input, the blood glucose monitoring device is determined from each candidate blood glucose monitoring device; if the target binding mode is the second binding mode, the device identifier input by the user is obtained, and the blood glucose monitoring device is determined based on the device identifier.

[0367] In this embodiment, taking the first binding mode as the aforementioned automatic binding 1201 as an example, if the user selects automatic binding 1201, the processor will search for candidate blood glucose monitoring devices within a preset search range. The preset search range can be set as needed, and each candidate blood glucose monitoring device within the preset search range will periodically broadcast its own device identification, so that the processor can perform the search.

[0368] Furthermore, the processor may display candidate blood glucose monitoring devices on the touch screen, allowing the user to select one of the candidate blood glucose monitoring devices as the blood glucose monitoring device. The selection input may be a sliding selection input, for example, the user may slide up and down on the touch screen to select a blood glucose monitoring device from the candidate blood glucose monitoring devices.

[0369] Taking the manual binding 1202 described above as the first binding mode as an example, if the user selects automatic binding 1201, the processor will receive the device identifier input by the user. The processor will then determine the blood glucose monitoring device based on the device identifier. Optionally, the processor will search for blood glucose monitoring devices within a preset search range based on the device identifier. If the blood glucose monitoring device is found within the preset search range, the blood glucose monitoring device is also determined.

[0370] In one embodiment, if the processor fails to search within a preset search range N times in a row, a first search failure prompt may be displayed on the touch screen, prompting the user whether to retry. If the user chooses to retry, the processor may return to the search step. If the search fails after M consecutive attempts, a second search failure prompt may be displayed on the touch screen. N and M can be set as needed and can be integers greater than 0.

[0371] In the above embodiment, if the target binding mode is the first binding mode, candidate blood glucose monitoring devices within a preset search range are searched, and a blood glucose monitoring device is determined from the candidate blood glucose monitoring devices in response to a user's selection input; if the target binding mode is the second binding mode, a device identifier input by the user is obtained, and a blood glucose monitoring device is determined based on the device identifier. Therefore, different binding modes can be used to flexibly bind blood glucose monitoring devices.

[0372] In an exemplary embodiment, optionally, the graphic element further includes a CGM information graphic element; and the device control method further includes the following steps:

[0373] In response to interactive operations on the CGM information graphic element, a preset information interface is displayed on the touch screen; the preset information interface includes device information of the blood glucose monitoring device.

[0374] In this embodiment, please continue to refer to Figure 11 , the user can click on the CGM information graphic element 1103, and then the insulin infusion device can respond to the interactive operation on the CGM information graphic element 1103 and display a preset information interface on the touch screen. The preset information interface may include device information of the blood glucose monitoring device. The device information may include the device identification SN, calibration code, and activation time. The device identification is used to uniquely identify the blood glucose monitoring device, the calibration code is used to indicate the sensor batch in the blood glucose monitoring device, and the activation time is used to identify the activation time of the blood glucose monitoring device.

[0375] In the above embodiment, since the graphic element also includes a CGM information graphic element and can display a preset information interface on the touch screen in response to interactive operations on the CGM information graphic element, and the preset information interface includes device information of the blood glucose monitoring device, the user can conveniently view the device information of the blood glucose monitoring device.

[0376] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0377] In response to the interactive operation for ending the wearing of the graphic element, the blood glucose monitoring device is unbound.

[0378] In this embodiment, the preset information interface further includes an end-wearing graphic element. The user can click on the end-wearing graphic element to initiate an interactive operation on the end-wearing graphic element. Then, the processor can unbind the blood glucose monitoring device in response to the interactive operation on the end-wearing graphic element.

[0379] Optionally, the processor may delete the device identification of the blood glucose monitoring device to unbind the blood glucose monitoring device.

[0380] In one embodiment, after unbinding the blood glucose monitoring device, the processor may display an unbinding prompt on the touch screen, such as "Sensor will become inoperable, are you sure you want to end wearing?" After the user confirms, the processor prompts "Unbinding successful, please charge immediately." In some embodiments, if the unbinding fails, the processor may display an unbinding failure prompt on the touch screen.

[0381] In the above embodiment, since the preset information interface also includes an end-wearing graphic element and can unbind the blood glucose monitoring device in response to the interactive operation on the end-wearing graphic element, the user can also unbind the blood glucose monitoring device in time if he does not need to wear the blood glucose monitoring device.

[0382] In an exemplary embodiment, optionally, the above device control method may further include the following steps:

[0383] In response to an interactive operation on a parameter graphic element displayed on the touch screen, a value of the control parameter is determined.

[0384] For example, please refer to Figure 8 , the graphic element also includes a parameter graphic element 804; after the user clicks the parameter graphic element 804, the touch screen can display a control parameter setting interface, which is used to set various control parameters.

[0385] Figure 13 This is a control parameter setting interface in an embodiment. Figure 13 For example, the control parameter setting interface 1300 includes a DIA graphic element 1301, a BG graphic element 1302, an ICR graphic element 1303 and an ISF graphic element 1304. The DIA graphic element 1301 is used to set the insulin active retention time, the BG graphic element 1302 is used to set the target blood glucose, the ICR graphic element 1303 is used to set the carbohydrate coefficient, and the ISF graphic element 1304 is used to set the insulin sensitivity coefficient.

[0386] For example, the user clicks on the DIA graphic element 1301 and enters the desired insulin active retention time. The insulin infusion device then obtains the value of the insulin active retention time in response to the user's input. Similarly, the insulin infusion device can determine the value of the control parameter.

[0387] In the above embodiment, since the graphic element also includes a parameter graphic element and is capable of determining the value of a control parameter in response to an interactive operation on the parameter graphic element, and the control parameter includes at least one of the insulin active retention time, target blood glucose, carbohydrate coefficient, and insulin sensitivity coefficient, the user can flexibly and quickly set the control parameter through the parameter graphic element on the touch screen.

[0388] In an exemplary embodiment, optionally, the graphic element further includes an object parameter graphic element; and the device control method further includes the following steps:

[0389] In response to an interactive operation on an object parameter graphic element displayed on the touch screen, a physiological parameter of the object to be measured is acquired, and a value of a control parameter is determined according to the physiological parameter.

[0390] In this embodiment, please continue to refer to Figure 8 The graphical element includes an object parameter graphical element 803. The user can click on the object parameter graphical element 803 and then enter the physiological parameters of the subject to be measured. Physiological parameters may include, but are not limited to, weight. The insulin infusion device can then obtain the physiological parameters of the subject to be measured and determine the values ​​of the control parameters based on the physiological parameters.

[0391] Optionally, the insulin infusion device can store the correspondence between different physiological parameters and control parameters. Then, after obtaining the physiological parameters of the subject to be measured, the value of the control parameter can be determined according to the physiological parameters of the subject to be measured and the above correspondence.

[0392] In the above embodiment, since the physiological parameters of the object to be measured can be obtained in response to the interactive operation on the object parameter graphic element, and the value of the control parameter can be determined according to the physiological parameters, the efficiency of setting the control parameter is improved.

[0393] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0394] In response to an interactive operation on the parameter viewing graphic element, a value of the control parameter is displayed on the touch screen.

[0395] In this embodiment, please continue to refer to Figure 9 The user can click on the parameter viewing graphic element 903, and then the insulin infusion device can respond to the interactive operation on the parameter viewing graphic element 903 and display the value of the control parameter on the touch screen.

[0396] In one embodiment, the insulin infusion device may also display the connection status with the blood glucose monitoring device when controlling the value of the parameter, for example, using "on" to indicate that the connection with the CGM is normal.

[0397] In the above embodiment, since the graphic element also includes a parameter viewing graphic element and can display the value of the control parameter on the touch screen in response to an interactive operation on the parameter viewing graphic element, the user can conveniently view the control parameter.

[0398] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0399] When the infusion dose or the single infusion dose within the fourth preset time period is greater than or equal to the corresponding maximum infusion dose threshold, in response to an interactive operation on the large-dose infusion graphic element, a first infusion prompt is displayed on the touch screen; in response to a confirmation input on the first infusion prompt, the interface returns to the location of the large-dose infusion graphic element.

[0400] In this embodiment, the fourth preset duration can be set as needed, for example, 4 hours or 1 day. The maximum infusion dose threshold is also set as needed. For example, the maximum infusion dose threshold corresponding to a single infusion dose is the maximum bolus dose, the maximum infusion dose threshold corresponding to an infusion dose within 4 hours is twice the maximum bolus dose, and the maximum infusion dose threshold corresponding to an infusion dose within a day is three times the maximum bolus dose.

[0401] Then, when the user needs to infuse a large dose, he will click on the large dose infusion graphic element 1002. If the infusion dose or the single infusion dose within the fourth preset time period is greater than or equal to the corresponding maximum infusion dose threshold, it means that the remaining infusion amount is 0, and then the insulin infusion device will display the first infusion prompt on the touch screen to prompt the user to infuse the dose to reach the upper limit. After the user confirms the first infusion prompt, the insulin infusion device will respond to the confirmation input for the first infusion prompt and return to the interface where the large dose infusion graphic element 1002 is located, for example, return to Figure 6 The menu page 300 is shown, indicating that the bolus infusion has been exited.

[0402] In the above embodiment, since, in the case where the infusion dose or the single infusion dose within the fourth preset time period is greater than or equal to the corresponding maximum infusion dose threshold, in response to an interactive operation on the bolus infusion graphic element, a first infusion prompt is displayed on the touch screen, and in response to a confirmation input on the first infusion prompt, the interface where the bolus infusion graphic element is located is returned to. Therefore, when the user needs to perform a bolus infusion, if the infusion dose or the single infusion dose within the fourth preset time period is greater than or equal to the corresponding maximum infusion dose threshold, the user can be prevented from continuing the bolus infusion, thereby improving safety during the use of the insulin infusion device.

[0403] In an exemplary embodiment, optionally, the device control method further includes the following steps:

[0404] In the case that a large dose infusion has been performed within the fifth preset time period, a second infusion prompt is displayed on the touch screen in response to an interactive operation on the large dose infusion graphic element.

[0405] In this embodiment, the fifth preset duration can also be set as needed, for example, to 1 hour. When a user needs to administer a bolus infusion, they click the bolus infusion graphic element 1002. If the insulin infusion device determines that a bolus infusion has already been administered within the fifth preset duration, a second infusion prompt, such as "Infused 1 hour ago," will be displayed on the touch screen. It should be noted that after the user confirms the second infusion prompt, i.e., in response to the confirmation input for the second infusion prompt, the insulin infusion device will continue the subsequent process of the bolus infusion graphic element.

[0406] In the above embodiment, if a large dose is infused within the fifth preset time period, a second infusion prompt is displayed on the touch screen in response to an interactive operation on the large dose infusion graphic element. Therefore, the user can be promptly notified that an excessive dose has been infused, thereby reducing the need for repeated infusions and improving safety.

[0407] It should be understood that, although the various steps in the flowcharts involved in the various embodiments described above are displayed in sequence according to the instructions of the arrows, these steps are not necessarily executed in sequence in the order indicated by the arrows. Unless otherwise specified herein, there is no strict order restriction on the execution of these steps, and these steps can be executed in other orders. Moreover, at least a portion of the steps in the flowcharts involved in the various embodiments described above can include multiple steps or multiple stages, and these steps or stages are not necessarily executed and completed at the same time, but can be executed at different times, and the execution order of these steps or stages is not necessarily to be carried out in sequence, but can be executed in turn or alternately with other steps or at least a portion of steps or stages in other steps.

[0408] Based on the same inventive concept, in one embodiment, Figure 1 As shown, an insulin infusion device 100 is also provided. The insulin infusion device 100 includes a touch screen 101 , at least one memory 102 and at least one processor 103 .

[0409] In one embodiment, the insulin infusion device may be a wearable or ambulatory insulin infusion device.

[0410] The touch screen 101 is configured to receive user input. The memory 102 stores executable instructions corresponding to the user input. The processor 103 is configured to execute the executable instructions to implement any of the aforementioned device control methods. The principles of the insulin infusion device can be found in the aforementioned description of the device control method and will not be further elaborated herein.

[0411] In one embodiment, a computer device is provided, including a memory and a processor. The memory stores a computer program, and the processor implements the steps in the above method embodiments when executing the computer program.

[0412] In one embodiment, a computer-readable storage medium is provided, on which a computer program is stored. When the computer program is executed by a processor, the steps in the above-mentioned method embodiments are implemented.

[0413] In one embodiment, a program product is provided, including a computer program, which implements the steps in the above method embodiments when executed by a processor.

[0414] In one embodiment, a closed-loop infusion system is provided, which includes any one of the above-mentioned insulin infusion devices 100 .

[0415] It should be noted that the user information (including but not limited to user device information, user personal information, etc.) and data (including but not limited to data used for analysis, stored data, displayed data, etc.) involved in this application are all information and data authorized by the user or fully authorized by all parties, and the collection, use and processing of relevant data must comply with relevant regulations.

[0416] Those skilled in the art will appreciate that all or part of the processes in the above-mentioned embodiment methods can be implemented by instructing the relevant hardware through a computer program, and the computer program can be stored in a non-volatile computer-readable storage medium. When the computer program is executed, it can include the processes of the embodiments of the above-mentioned methods. Among them, any reference to memory, database or other media used in the embodiments provided in this application may include at least one of non-volatile memory and volatile memory. Non-volatile memory may include read-only memory (ROM), magnetic tape, floppy disk, flash memory, optical memory, high-density embedded non-volatile memory, resistive random access memory (ReRAM), magnetic random access memory (MRAM), ferroelectric random access memory (FRAM), phase change memory (PCM), graphene memory, etc. Volatile memory may include random access memory (RAM) or external cache memory, etc. By way of illustration and not limitation, RAM can be in various forms, such as static random access memory (SRAM) or dynamic random access memory (DRAM). The database involved in the various embodiments provided herein may include at least one of a relational database and a non-relational database. Non-relational databases may include, but are not limited to, distributed databases based on blockchains. The processor involved in the various embodiments provided herein may be, but are not limited to, a general-purpose processor, a central processing unit (CPU), a graphics processing unit (GPU), a digital signal processor (DSP), a programmable logic unit (PLC), a data processing logic unit based on quantum computing, an artificial intelligence (AI) processor, and the like.

[0417] The technical features of the above embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this application.

[0418] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present application. It should be noted that a person of ordinary skill in the art may make various modifications and improvements without departing from the spirit of the present application, and these modifications and improvements fall within the scope of protection of the present application. Therefore, the scope of protection of the present application shall be determined by the appended claims.

Claims

1. A device control method, characterized in that: The method is applied to an insulin infusion device, which includes a touch screen, at least one memory, and at least one processor. The touch screen is used to receive user input, the memory stores executable instructions, and the processor executes the executable instructions to implement the following method: In response to a first interactive operation of a user on a parameter graphic element displayed on the touch screen, obtaining a control parameter input by the user; In response to a second interaction operation of the user on the device connection graphic element displayed on the touch screen, establishing a communication connection with the blood glucose monitoring device through the second interaction operation to receive the blood glucose measurement value sent by the blood glucose monitoring device; In response to a third interaction operation of the user with respect to the mode start graphic element displayed on the touch screen, the closed-loop operation mode is started through the third interaction operation; wherein, if a communication connection with the blood glucose monitoring device is not established, starting the closed-loop operation mode is prohibited; In the case of running the closed-loop operation mode, controlling the insulin infusion device to run the corresponding infusion mode according to the blood glucose measurement value, the historical infusion data and the control parameter; Monitoring whether a blood glucose impact event occurs during operation in the closed-loop operation mode; the blood glucose impact event includes an event in which the user's blood glucose level deviates from the target blood glucose range of the control parameter due to device operation and / or user activity; When it is determined that the blood sugar impact event occurs, triggering a safety protection program; The closed-loop operation mode of the insulin infusion device is safely managed through the safety protection program.

2. The device control method according to claim 1, wherein: The blood sugar impact event includes a user exercise event, and the processor is further configured to implement the following method: Receiving motion information collected by a motion sensor or input by a user; determining whether the user motion event occurs according to the motion information; When it is determined that the user motion event occurs, triggering the security protection program; Obtaining a blood glucose measurement value at the current moment when the user's exercise event occurs, and determining a blood glucose prediction value based on the exercise information, the blood glucose measurement value, and historical blood glucose data; Determining the infusion dose of the temporary basal rate according to the predicted blood glucose value and the control parameter through the safety protection program; According to the infusion dose of the temporary basal rate, the insulin infusion device is controlled to run a temporary basal rate infusion mode.

3. The device control method according to claim 1, wherein: The blood sugar impact event includes a user meal event; the processor is further configured to implement the following method: Determine the current blood sugar prediction value based on historical blood sugar data; determining whether the user has eaten a meal based on a blood glucose difference between a current blood glucose measurement value and a predicted blood glucose value at the current moment, and / or a meal monitoring sensor worn by the user; When it is determined that the user dining event occurs, triggering the safety protection program; Determining the infusion dose of the temporary basal rate according to the predicted blood glucose value and the control parameter through the safety protection program; According to the infusion dose of the temporary basal rate, the insulin infusion device is controlled to run a temporary basal rate infusion mode.

4. The device control method according to claim 1, wherein: The processor is further configured to implement the following method: Obtaining a carbohydrate value input by a user through the touch screen; the carbohydrate value is used to represent the total amount of food consumed by the user; Triggering the safety protection program according to the carbohydrate value; determining, by the safety protection program, a first bolus dose based on the carbohydrate value, a blood glucose measurement value associated with the carbohydrate value input by the user at the current moment, and the control parameter; According to the first first large dose, controlling the insulin infusion device to operate in a large dose infusion mode; Determining a predicted blood glucose value based on the blood glucose measurement value at the next moment after the current moment; Determining a first large supplemental dose according to the predicted blood glucose value and the control parameter through the safety protection program; According to the first supplemental bolus, the insulin infusion device is controlled to run the bolus infusion mode.

5. The device control method according to claim 1, wherein: The processor is further configured to implement the following method: obtaining a pre-meal bolus dose input by a user through the touch screen; Triggering the safety protection program by the large dose before the meal; Controlling the insulin infusion device to operate in a bolus infusion mode according to the pre-meal bolus through the safety protection program; Determine a predicted blood sugar value based on the blood sugar measurement value at the next moment after the current moment; Determining a third supplemental large dose according to the predicted blood glucose value and the control parameter through the safety protection program; According to the third supplemental bolus, the insulin infusion device is controlled to run the bolus infusion mode.

6. The device control method according to claim 1, wherein: The processor is further configured to implement the following method: receiving an initial infusion dose for implementing a bolus infusion mode; monitoring, by the safety protection program, whether the initial infusion dose reaches a first infusion limit and a second infusion limit; When the initial infusion dose does not reach the first infusion limit and the second infusion limit, the insulin infusion device is controlled to operate the large-dose infusion mode; wherein the first infusion limit is used to constrain the total of the large-dose infusion doses cumulatively input within a preset time period, and the second infusion limit is used to constrain the total of the large-dose infusion doses cumulatively input within the day.

7. The device control method according to claim 6, characterized in that: When the initial infusion dose reaches the first infusion limit or the second infusion limit, the processor is further configured to implement at least one of the following methods: calculating a dose difference between the initial infusion dose and the first infusion limit or the second infusion limit, and controlling the insulin infusion device to infuse the dose difference; or; receiving an initial infusion dose input by a user on the touch screen; When the initial infusion dose reaches both the first infusion limit and the second infusion limit, the touch screen is controlled to display a setting prompt to remind the user to reset the initial infusion dose.

8. The device control method according to claim 6, characterized in that: The processor is further configured to: In response to a fourth interactive operation performed by the user on the meal assistance graphic element displayed on the touch screen, obtaining a carbohydrate value inputted by the fourth interactive operation; receiving a current blood glucose measurement value corresponding to the moment when the user inputs the carbohydrate value; generating a recommended bolus dose according to the carbohydrate value and / or the current blood glucose measurement value through the safety protection program; responding to a fifth interactive operation by the user on a high-dose graphic element displayed on the touch screen; The initial infusion dose is set with reference to the recommended large dose according to the fifth interactive operation.

9. The device control method according to claim 3, wherein: The processor is further configured to implement the following method: Determining the current blood glucose prediction value based on the historical blood glucose data, and determining a meal estimation value based on a blood glucose difference between the current blood glucose measurement value and the current blood glucose prediction value; Determining a micro-bolus dose according to the predicted blood glucose value, the estimated meal value, and the control parameter through the safety protection program; The insulin infusion device is controlled to operate in a bolus infusion mode according to the micro-bolus.

10. The device control method according to any one of claims 1 to 9, characterized in that: The processor is further configured to implement at least one of the following methods: When it is determined that a hypoglycemic event of the user occurs during the operation of the closed-loop operation mode, controlling the insulin infusion device to suspend infusion through the safety protection program; or, monitoring whether the insulin infusion device is operating in a standard basal rate infusion mode if it is determined that a hypoglycemic event of the user has occurred during operation in the closed-loop operation mode; When it is determined that the insulin infusion device is operating in the standard basal rate infusion mode, adjusting the standard basal rate infusion mode to a temporary basal rate infusion mode through the safety protection program, and setting the infusion dose of the temporary basal rate to a safe dose; or, monitoring whether the insulin infusion device is operating in a temporary basal rate infusion mode if it is determined that a hypoglycemic event of the user has occurred during operation in the closed-loop operation mode; When it is determined that the insulin infusion device is operating in the temporary basal rate infusion mode, setting the temporary basal rate infusion dose to the safe dose through the safety protection program; or, In the case where a hypoglycemic event of the user is detected during the operation of the closed-loop operation mode, monitoring whether the insulin infusion device is simultaneously operating the temporary basal rate infusion mode and the bolus infusion mode; When it is determined that the insulin infusion device is operating in the temporary basal rate infusion mode and the large dose infusion mode, stopping the large dose infusion mode through the safety protection program, and setting the infusion dose of the temporary basal rate to a safe dose through the safety protection program; or, monitoring whether the insulin infusion device is operating in the bolus infusion mode when a hypoglycemic event of the user is detected during the closed-loop operation mode; When it is determined that the insulin infusion device is running the large-dose infusion mode, the large-dose infusion mode is stopped through the safety protection program, the temporary basal rate infusion mode is run through the safety protection program, and the temporary basal rate infusion dose is set to a safe dose.

11. The device control method according to claim 10, characterized in that: After switching the closed-loop operation mode to the open-loop operation mode, the processor is further configured to implement at least one of the following methods: After the user's hypoglycemia event is resolved, in response to the user's sixth interactive operation of starting a graphical element for a mode displayed on the touch screen, controlling the insulin infusion device to resume the closed-loop operation mode; Alternatively, when it is monitored that the blood glucose measurement value is higher than the blood glucose recovery threshold and the insulin infusion device is in the state of suspended infusion, the insulin infusion device is controlled to automatically resume the closed-loop operation mode.

12. The device control method according to any one of claims 1 to 9, characterized in that: The processor is further configured to implement at least one of the following methods: When it is determined that an abnormal blood sugar event or a blood sugar loss event occurs during the operation of the closed-loop operation mode, maintaining the closed-loop operation mode through the safety protection program; monitoring whether the insulin infusion device is running in a temporary basal rate infusion mode; if it is determined that the insulin infusion device is running in the temporary basal rate infusion mode, switching the temporary basal rate infusion mode to a standard basal rate infusion mode; Alternatively, if it is determined that an abnormal blood sugar event or a blood sugar loss event occurs during the operation of the closed-loop operation mode, the closed-loop operation mode is maintained by the safety protection program; and whether the insulin infusion device is operating in a large-dose infusion mode; When determining that the insulin infusion device is running the bolus infusion mode, maintaining the bolus infusion mode; or, When it is determined that an abnormal blood sugar event or a blood sugar loss event occurs during the operation of the closed-loop operation mode, maintaining the closed-loop operation mode through the safety protection program; monitoring whether the insulin infusion device is operating in a standard basal rate infusion mode; In case of monitoring that the insulin infusion device is running the standard basal rate infusion mode, the standard basal rate infusion mode is maintained.

13. The device control method according to any one of claims 1 to 9, characterized in that: The processor is configured to implement the following method: When a high-level alarm event is determined to occur during the operation of the closed-loop operation mode, the closed-loop operation mode is switched to the open-loop operation mode through the safety protection program, and the high-level alarm event is safely managed.

14. The device control method according to claim 13, characterized in that: The high-level alarm event includes a first alarm event, and the processor is further configured to implement the following method: According to the safety management of the first alarm event by the safety protection program, the insulin infusion device is controlled to suspend infusion; wherein, the first alarm event includes at least one of an excessively strong ambient magnetic field, depletion of medicine, detachment of the pipeline, depletion of power, and pipeline blockage.

15. The device control method according to claim 13, wherein: The high-level alarm event includes a second alarm event, and the processor is further configured to implement at least one of the following methods: According to the safety management of the second alarm event by the safety protection program, controlling the temporary basal rate infusion mode currently running on the insulin infusion device to switch to the standard basal rate infusion mode; Alternatively, according to the safety management of the second alarm event by the safety protection program, the insulin infusion device is controlled to maintain the operation of the standard basal rate infusion mode; The second alarm event includes that the service life of the blood glucose monitoring device is insufficient.

16. An insulin infusion device, characterized in that: The insulin infusion device includes a touch screen, at least one memory and at least one processor, wherein the memory stores executable instructions, and the processor is configured to execute the executable instructions to implement the method according to any one of claims 1 to 15.

17. A program product, characterized in that The program product is executed by a processor to implement the method according to any one of claims 1 to 15.

18. A closed-loop infusion system, characterized in that: The closed-loop infusion system comprises the insulin infusion device of claim 16.

Images